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Oligonucleotides are capable of forming triple helices by binding
within the major groove of a DNA duplex target. While DNA within the cell is
believed to be in the B-form, triple helices have been found to be A'-form.
This would require a B->A' transition either prior to, or concurrent with,
triple helix formation. A systematic computer search has been carried out
for oligonucleotide analogues capable of binding to B-form DNA. These
analogues are modeled after netropsin/distamycin type structures which are
known to be nearly isohelical with B-form DNA. Initial synthetic efforts
toward the nucleoside components of one favorable analogue are also
reported.
DNA triple helices are currently limited to polypyrimidinepolypurine
stretches of DNA. Specificity is gained through FAT, C-FGC or GGC base
triplets. An investigation of two novel recognition moieties, inosine and 7-
deazaadenine, has been performed. Inosine would replace T of a FAT triplet
to form FAT triplets, while 7-deazaadenine would replace C of a C-FGC triplet
to form 7dA+GC triplets. Triple helices of poly(rI)poly(rA)poly(dT) have
been reported previously. The higher pka of 7dA (5.3) as compared to
Redacted for Privacycytidine (4.3) would improve the pH dependence of triple helix formation 
using this motif.  Investigations of oligomers containing these nucleosides 
failed, however,  to demonstrate triple helix formation by UV melting curve 
experiments or gel mobility shift assays. Design of B-form Specific DNA Binding Oligonucleotide Analogues.
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 DESIGN OF B-FORM SPECIFIC DNA BINDING OLIGONUCLEOTIDE 
ANALOGUES. INVESTIGATIONS OF NOVEL RECOGNITION MOIETIES 
FOR TRIPLE HELIX FORMATION. 
INTRODUCTION 
The DNA double helix offers three channels of recognition:  the 
phosphate backbone; the minor groove and the major groove (figure 1). The 
phosphate backbone offers  the  least amount of sequence specific 
information to DNA binding ligands. At first glance, the only interaction 
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Figure 1. DNA double helix. Unwound and shown in detail(left), shown 
schematically (reprinted with permission from ref.2a copyright 1988 AAAS) 
with major and minor grooves indicated(right). 2 
offered would appear to be an electrostatic one although other variables such 
as interphosphate distances (groove widths) and deoxyribose conformation 
provide additional yet more elusive information. 
Complementary hydrogen-bonding in the minor or major grooves of 
the double helix is the only mechanism that can recognize and discriminate 
individual base pairs. The minor groove, although less informative than the 
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Figure 2. Information content of base pairs. Major groove is above, minor 
groove is below each base pair representation (d=hydrogen bond donor, 
a=hydrogen bond acceptor). Reprinted with permission from ref. 1. 
major groove does offer some sequence information (figure 2)1. The GC base 
pair presents two hydrogen-bond acceptors (guanine-N2 and cytosine-02) 3 
and one hydrogen-bond donor (guanine-C2-NH2). The AT base pair offers 
only two hydrogen-bond acceptors (adenine-N3 and thy-mine-02).  The 
problem of specific recognition lies in discriminating between GC-which 
offers a hydrogen-bond acceptor-donor-acceptor pattern and CG which also 
offers an acceptor-donor-acceptor pattern.  This situation is not as difficult 
as the AT/TA recognition problem .  While the GC/CG comparison offers the 
same pattern of hydrogen-bond acceptors/donors, they are not symmetrical. 
The AT/TA base pairs  offer two hydrogen - bond acceptors nearly 
leucine zipper (reprinted 
with permission from 4 copy­
right 1990 AAAS) 
helix-turn-helix 
(reprinted with permission from 
2a copyright 1988 AAAS) 
*­
anti-parallel p-sheets 
(reprinted with permission 
Zn-finger (with  from Natures, 1990 Macmillan 
permission from 2b)  Magazines Limited) 
Figure 3. Protein-DNA binding motifs. 4 
symmetrically positioned (with respect to the backbone attachment sites) in 
the groove; this is particularly evident in the stick figure representation 
(figure 2). 
The most detailed sequence information is found in the major groove. 
AT base pairs are easily distinguished from TA base pairs.  The pattern of 
hydrogen-bond acceptor (adenine-N7), hydrogen-bond donor (adenine-C6­
NH2), hydrogen-bond acceptor (thymine-04) and the protrusion of the 
thymine methyl group into the major groove is easily differentiated from the 
reverse pattern.  In addition, the non-symmetrical hydrogen-bond acceptor 
(guanine-N7), hydrogen-bond acceptor (guanine-06), hydrogen-bond donor 
(cytosine-C4-NH2) pattern of a GC base pair is clearly differentiable from the 
opposite pattern of a CG base pair. 
In nature, all information offered by the DNA helix is exploited by 
sequence specific binding proteins.  Four types of structural motifs-the 
helix-turn-helix, the Zn-fingers, the Leu-zippers, and the antiparallel  13­
sheets have been identified which are responsible for DNA recognition 
(figure 3).  The majority of sequence-specific DNA-binding proteins 
recognize DNA from the major groove.  The helix-turn-helix proteins 
recognize a particular sequence of DNA through hydrogen-bond interactions 
of their a3 helices and the major groove of DNA2a. It is also postulated that 
Leu-zipper proteins recognize DNA through the use of a helices.  In this case 
two a-helices held together by a Leu-zipper are placed in the major groove of 
DNA3. An antiparallel 13-sheet followed by an a-helix has been proposed for 
Zn-finger proteins2.  Proteins that bind via the antiparallel 13-sheet motif 
also bind within the major groove of DNA5­
Small molecules that interact with DNA can be divided into two major 
categories:  intercalators and groove binders. While intercalation does not 5 
provide much sequence discrimination,  intercalators which exhibit 
sequence selectivity normally gain  this by hydrogen-bonding and 
hydrophobic interactions of appended side chains to sites within the minor 
groove.  Anthracycline drugs such as daunomycin (figure 4) are anticancer 
drugs that intercalate in DNA and inhibit replication and transcription. 
Daunomycin has been shown to intercalate at the d(CG) sequences of the 
hexanucleotide d(CGTACG) 6. The aglycone chromophore positions itself with 
the D ring protruding into the major groove and the A ring lying in the 
minor groove.  Specific interactions between daunomycin and DNA include 
hydrogen bonds between the hydroxyl group 09 of daunomycin and the N3 
and C2-NH2 of guanine, and the C2-NH2 of guanine and the 07 atom of the 
glycosyl ether linkage. 
O 
H3C 
Figure 4. Structure of daunomycin. 
The quinoxaline antibiotics such as echinomycin (figure 5) are 
sequence specific intercalators which gain their specificity through 
hydrogen bonding between the peptide backbone and the minor groove of 
the DNA double helix7 specifically between the alanine residues and the 
guanine bases.  Echinomycin binds in the minor groove with the two 
quinoxaline rings stacking on either side of two GC base pairs (figure 6). The 6 
binding constant ratio of echinomycin8 for high affinity vs. low affinity 
sites is only 10-20, by comparison that for lac-repressor9 (a helix-turn-helix 
protein) is 105. 
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Figure 5. Structure of echinomycin. 
Q13 
Figure 6. Binding model of echinomycin to DNA. Reprinted by permission 
of Oxford University Press from ref. 7. 
An example of base specific non-intercalative DNA binding molecules 
are the antitumor antibiotics netropsin and distamycin (figure 7). These 7 
molecules are known to bind in the minor groove of B-form DNA interfering 
with both replication and transcription. They show a binding preference 
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Figure 7. Structure of netropsin (left) and distamycin (right). 
for AT-rich sequences with continuous runs of A or T proving better than 
alternating A-T regions.  X-ray diffraction analysis of a netropsin-B-DNA 
dodecamer10 revealed the specific contacts made between netropsin and the 
minor groove of DNA. The amide N-H groups of netropsin form bifurcated 
hydrogen bonds to adjacent adenine N3 and thymine 02 atoms on opposite 
strands of the helix.  Electrostatic and van der Waals interactions also play a 
role in stabilizing the complex. Both netropsin and distamycin are positively 
charged molecules and it is found that these positively charged ends lie in 8 
the center of the minor groove rather than associated with specific 
phosphates. This is consistent with the suggestion that the deepest negative 
charge potential of a DNA double helix is near the bottom of the minor 
groove at AT regions' 1.  Close van der Waals contacts between the pyrrole 
HC3 hydrogens and adenine HC2 hydrogens point to further reason for AT 
binding preference.  Severe steric hindrance would result between 
hydrogen atoms of the pyrrole rings of these drugs and N2 amino groups of 
guanine bases in the minor groove. This discovery led to numerous studies of 
netropsin analogues termed lexitropsins.  In these molecules one or more 
pyrrole rings are replaced by other heterocycles in hopes of targeting GC 
base pairs12 (figure 8). This eliminates the pyrrole HC3 hydrogens atoms and 
provides a hydrogen bond acceptor in the case of imidazole substitution to 
interact with the guanine N2 amino group.  Binding studies with these new 
reagents were disappointing however.  These molecules demonstrated an 
increased tolerance for GC base pairs, though not GC specificityl 3. 
Interestingly, it was found that analogues containing thiazole rings with the 
sulfur atom pointed toward the minor groove exhibited a greater specificity 
for AT rich regions than does netropsin. The authors site steric hindrance 
between the sulfur atom and guanine amino groups as the cause. 
As mentioned above, the deep negative charge potential of the minor 
groove at AT regions is thought to have a large influence in attracting the 
doubly charged netropsin molecules.  This led investigators to examine 
monocationic lexitropsins similar to distamycin A in hopes of easing the AT 
preference 14.  One compound having two N-methylimidazole residues in 
place of the N-methylpyrrole rings preferred to bind to a 5'-CCGT-3' 
sequence. 9 
Due to the bifurcated hydrogen bonding pattern, it is known that 
netropsin and related molecules with n amide units bind to an AT site of n+1 
base pairs. In an effort to design molecules that could bind to unique sites in 
a given genome (15-16 by in the human genome) longer analogues have 
been synthesized15. These molecules (n=4-7) were found to bind to AT rich 
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Figure 8. Lexitropsin structures. 
sites of n+1 base pairs, though it was noted that binding of longer and longer 
analogues begins to become less favorable as the length of the polymer 
increases. This phasing problem is due to the fact that these molecules are 
slightly too long to match the helical path of B-form DNA. 
The above studies have led to the development of lexitropsins 
containing only one charge-to minimize the AT preference-and three amide 10 
units-to minimize the phasing problem.  One study16 showed that a 
distamycin A analogue containing one imidazole ring specifically recognizes 
the sequence AAGTT while no specific binding to the site AAATT was 
observed.  It is now believed that lexitropsin molecules can be designed to 
specifically recognize many DNA sequences of four to five base pairs in 
length. 
The major groove, carrying more sequence information than the 
minor groove, is the logical target for molecules designed to interact with 
DNA. It has been known for some time that single stranded polymers of RNA 
bind to polymers of double-stranded RNA.  In 195717 it was reported that 
poly(U) forms a three stranded complex (triplex) with a poly(rA)-poly(U) 
Watson-Crick duplex.  It was postulated that the second poly(U) strand was 
bound within the major groove of the poly(rA)-poly(U) duplex. A similar 
interaction was observed between poly(rC) and a poly(rC)-oligo(rG) duplex in 
196418. A pH dependence was observed in this study and a hydrogen bonding 
scheme was proposed in which one of the cytosines is protonated at N3. The 
specificity of these interactions is derived from Hoogsteen hydrogen 
bonding between A and U residues or G and C+ residues resulting in UAU or 
C+-GC triplets (Hoogsteen I (HI) pairing, figure 9).  Several years later fiber 
diffraction studies of the poly(U)poly(rA)poly(U) system19 revealed more 
details of these structures.  The conformations of the individual sugar-
phosphate chains are all of the A family characterized by C3'-endo puckered 
furanose rings. The Hoogsteen poly(U) strand sits in the major groove of the 
anti-parallel poly(rA)poly(U) double helix and is parallel to the poly(rA) 
chain (figure 10).  It was suggested by these authors that triple stranded 
complexes should be possible wherever a continuous sequence of purine 
nucleotides exists in a nucleic acid chain.  Indeed, several other examples 11 
were soon reported such as poly(dT)-poly(dA)-poly(dT)21, poly(rI)-poly(rA)­
poly(rI)22, poly(dC)poly(dI) poly(dC)23, poly(rA)poly(U)-poly(rI)24,25, and 
poly(rA)poly(rT)-poly(rI)24.  All of these complexes exhibited the same 
overall structure as the poly(rU)poly(rA)-poly(rU) triplex. 
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Figure 9. UAU (above) and C+GC (below) triplets. 
Several authors have suggested possible biological functions for triple 
helices26-34 ranging from repression of gene expression29 to a model for 
chromosomal structure in higher organisms31. lack of evidence for any 
biological role however relegated triple helices to the status of "oddities of 
synthetic polymer interactions".  Advances in areas such as synthesis of 
oligodeoxynucleotides and separation techniques of large fragments of DNA 
however have made investigations of triple helix formation more feasible. 12 
Much work has been done with triple helices containing TAT and 
C-FGC triplets.  In 1987 Moser and Dervan35 demonstrated triple helix 
formation between a Watson-Crick duplex 30 base pairs (bp) in length and a 
third strand consisting of 15 thymidine residues one of which carries an 
EDTA residue. The EDTA, once complexed to Fe(II) and in the presence of 
Figure 10. Schematic of a triple helix. Reprinted with permission from ref. 
20 Copyright 1990 American Chemical Society. 
dithiothreitol and 02,results in the formation of hydroxyl radicals which 
cleave the backbone of one (or both) of the Watson-Crick  target duplex 
strands.  The asymmetric cleavage patterns of these EDTAFe(II) probes 
confirmed both the parallel orientation of the third strand relative to the 
purine strand and that the third strand binds within the major groove of the 
target duplex.  It was further demonstrated that oligonucleotides 11-15 by in 
length could bind sequence specifically to a 628 by restriction fragment  as 13 
well as to a linear DNA fragment 4.06 kbp in size produced from the plasmid 
pDMAG10. 
The effect of mismatches and length of the third strand were also 
investigated in this study.  Oligomers containing single base mismatches 
lowered the cleavage efficiency by a factor of 10, while oligomers 11 by in 
length demonstrated cleavage efficiencies  significantly weaker than 
oligomers 15 by in length at 25° C. 
In order for this approach to be extended to any sequence of DNA, 
several problems have to be addressed. Thus far, triple helices are limited to 
homopurine-homopyrimidine tracts involving recognition of A or G 
residues.  While regions like these have been discovered in the control 
regions of many eukaryotic genes, recognition of mixed sequences is still 
desirable.  Several attempts have been made using varied techniques at 
recognizing all four base pairs. One approach has been to link together two 
pyrimidine oligomers through a 3'-3' linker, thus forming an oligomer 
capable of forming an alternate-strand triple helix.  Horne and Dervan36 
linked together two C,T containing nonamers through a 3'-3' phosphodiester 
1,2-dideoxyribose linker. The resulting oligomer is capable of recognizing a 
stretch of nine base pairs on one strand, crossing over the major groove-
skipping over two base pairs in the process-and recognizing an additional 
nine base pairs on the opposite strand (figure 11). This oligomer was shown 
to bind to a plasmid DNA 4.05 kbp in size and produce a specific double-strand 
cleavage in 14% yield via an EDTAFe(II) attached to a thymidine residue. 
Substitution of the dideoxyribose linker by the acyclic linker 1,3-propanediol 
produced an oligomer which bound with three times less efficiency.  It was 
reported by Ono et al.37 however that octamers connected 3'-3' by a 
phosphate-propanediol-phosphate linker showed a Tm of the third strand 14 
26°C higher than that of two non-linked octamers. Other workers38,39 also 
showed oligomers containing a propanediol linker to have a Tm very similar 
to oligomers containing the dideoxyribose linker.  Investigation of a xylose 
linker showed it to have a Tm 13°C higher than the ribose or diol linked 
oligomers39. 
Further studies intent on extending triple helix formation to mixed 
sequences led to the discovery of a second structural motif40-42. Cooney and 
co-workers40 first demonstrated that a purine rich oligonucleotide could 
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Figure 11. Crossover triplexes. 3'-3' linked crossover (left, reprinted with
 
permission from ref. 36 copyright 1990 American Chemical Society),
 
pyrimidine/purine crossover (right).
 
bind site specifically within the 5' end of the human c-myc gene thus 
repressing transcription.  Sequence specificity was reported to be based on 
GGC and AAT base triplets.  Further investigations by Dervan and 
coworkers41,42 further elucidated the interactions taking place.  These 
purine rich oligonucleotides were found to bind in an anti-parallel 15 
orientation relative to the purine strand of the Watson-Crick duplex. 
Hydrogen bonding patterns were suggested based upon strand orientation 
and anti conformations of the bases (figure 12).  Beal and Dervan43 have 
reported that an alternate strand triple helix can be formed by combining 
the two different motifs.  Oligonucleotides containing a stretch of 
pyrimidines and a purine rich stretch can bind to a purine stretch on one 
strand of a Watson-Crick duplex followed by binding to a purine stretch on 
the other strand of the duplex.  The opposite polarity of the pyrimidine­
purine-pyrimidine motif as opposed to the pyrimidine-purine-purine motif 
Figure 12. GGC (above) and AAT triplets. 16 
makes this possible without the use of a linker.  It was found, through 
determination of differential reactivity to dimethyl sulfate, that two 
guanines located at the junction of the pyrimidine/purine-rich regions of 
the third strand are likely not involved in stable base triplets (figure 11). 
Further attempts at addressing the problem of targeting mixed 
sequences have included skipping over a particular base pair for which no 
mate is known. Within a 15mer oligothymidylate, Horne and Dervan44 placed 
one abasic 1,2-dideoxy-D-ribose (0) residue opposite one of the four base pairs 
resulting in 0.AT, 4GC, 4rTA, or O.CG triplets. These oligomers were found to be 
significantly less stable than those containing C4-GC/T-AT triplets, indicating 
that base stacking interactions are important for triple helix stability as are 
hydrogen bonding interactions. 
An additional problem with the pyrimidine-purine-pyrimidine motif 
is the necessity of cytosine protonation.  This excludes the probability of 
triplex formation in vivo where intracellular pH (7.0-7.4)  is  strictly 
regulated45. This matter has been addressed primarily by substituting some 
other base for cytosine which either doesn't require protonation or 
protonates at a higher pH.  Povsic and Dervan46 demonstrated triple helix 
formation in the physiological pH range by substituting 5-methylcytosine 
for cytosine. Due to the fact that the pKa of deoxycytidine is 4.3 and that for 
5-methyldeoxy cytidine is 4.4, the authors suggested that this extension of the 
pH range is due to a hydrophobic interaction of the methyl groups within 
the major groove.  Xodo et al.47 showed that methylation of cytosine 
enhances triplex stability.  These authors state that this enhanced stability 
appears to be entropic in origin. The methyl group fills a space in the major 
groove of the target duplex causing a release of water molecules, a source of 
positive entropy. 17 
Froehler and Ricca48 have demonstrated triple helix formation with 
oligomers  containing  the  carbocyclic  analogues  of 5-methy1-2'­
deoxycytidine and thymidine. Removal of the electron-withdrawing oxygen 
of the furanosyl ring causes a change in the pka of the parent heterocycle. 
The pka of 5- methyl -2'- deoxycytidine is 4.35 while that of the carbocyclic 
analogue is 4.80. Oligomers containing the 5-methylcytosine analogue were 
found to form more stable triplexes at pH 7.2 as compared to oligomers 
containing 5-methylcytosine.  Interestingly, oligomers containing the 
carbocyclic analogue of thymidine were found to be less stable than 
oligomers containing thymidine.  A crystal structure of the nucleoside 
indicates a C1'-exo pucker of the cyclopentane ring which may be 
unfavorable for triple helix formation. 
Koh and Dervan49 synthesized the pyrazole analogues P1 and P2 
(figure 13).  Each of these molecules provides a hydrogen-bonding pattern 
that would mimic an N-3 protonated cytosine. Results of this study showed P1 
to form Pl.GC triplets that were as stable as C+GC triplets. These authors had 
observed that the stabilities of complexes containing contiguous C+GC 
triplets decreased markedly with increasing pH.  An examination of 
complexes formed with double helical DNA containing a (G)6 sequence 
showed that third strands containing P1 form complexes up to pH 7.4 while 
those containing C or 5MeC form complexes at pH 6.2 but are less stable at pH 
6.6.  Oligomers containing the analogue P2 did not perform as well, the 
authors postulate an energetically unfavorable distortion of the third strand 
backbone or a preference for the syn conformation due to the methyl group 
to explain these results. 
Ono et a1.50 investigated the replacement of cytidine with 2'-0­
methylpseudoisocytidine (figure 13) in the third strand of a triplex.  This 18 
analogue also provides the proper hydrogen bonding scheme for 
complexation to G.  Oligomers containing this analogue were shown to form 
triple helices with a complementary target duplex at pH 7.  Oligomers 
containing cytidine or 2'- O- methylcytidine failed to show evidence of triplex 
formation under identical conditions.  Furthermore, oligomers containing 
the 2'- O- methylpseudoisocytidine showed triplex formation up to pH 8.7. 
Miller et al.5 1  demonstrated triple helix formation utilizing 8­
oxoadenine to target guanine bases. 8-0xoadenosine has been shown to exist 
in the keto form with the base in the syn conformation52 If this is the case, 
two hydrogen bonds can potentially form between guanine and 8-oxoadenine 
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Figure 13. Base analogues. 19 
(figure 13).  Oligomers containing this analogue were shown to be more 
stable at pH 8 as compared to oligomers containing cytosine. 
Krawczyk et al.53 demonstrated triple helix formation with third 
strands containing N6- methyl- 8- oxo -2'- deoxyadenosine  (MODA)  in 
substitution for 2'-deoxycytidine.  Oligomers containing MODA were 
compared with oligomers containing 5- methyl -2'- deoxycytidine as well as to 
oligomers containing 2'-deoxyguanosine, each opposite GC base pairs. Under 
conditions approximating known intracellular pH (7.2) and mono- and 
multivalent cation concentrations (140 mM KC1, 10 mM NaCI, 1 mM MgCl) 2 
only the oligomer containing MODA 
demonstrated complex formation.  Furthermore, an oligomer containing 
MODA with one mismatched triplet (MODATA) failed to demonstrate triplex 
formation indicating a high degree of specificity for the MODAG C 
interaction. 
Griffin  et a1.54 have attempted to extend recognition to all four 
possible Watson-Crick base pairs within a pyrimidine-purine-pyrimidine 
motif.  The nonnatural base components 4-phenylimidazole (D2) and 4(3­
benzamidophenyl)imidazole (D3) (figure 13) were chosen to target CG base 
pairs. D2 was designed to form one hydrogen bond between the imidazole N3 
and the cytosine NH2. D3 was designed to span both strands of the Watson-
Crick double helix and form two hydrogen bonds, one between the imidazole 
N3 and the cytosine NH2 and the other between the amide NH of D3 and the 06 
of guanine.  Oligomers containing D2 demonstrated only weak binding 
affinity opposite all four base pairs.  Oligomers containing D3 however 
showed efficient binding when opposite CG or TA base pairs.  This 
recognition is explained as being a result of an ensemble of van der Waals 
interactions rather than specific hydrogen bonding.  While this analogue 20 
does formally extend triple helix formation to all four base pairs, it fails to 
distinguish between CG and TA sites. 
Additional analogues, both in the field of triple helices and antisense 
agents, have been developed in which the structure of the backbone has 
been altered rather than that of the base. The need for backbone analogues 
arises from two sources.  In order for triple helix formation to take place 
within the  cell,  possibly for the purpose of genetic control, an 
oligonucleotide must be able to pass through cellular membranes and be 
stable to intracellular nucleases once inside the cell. 
Helene and coworkers55-57 have investigated the use of the unnatural 
a-anomers of oligonucleotides for triple helix formation.  These oligomers 
have been shown to be nuclease resistant.  These workers have shown that 
an [a]-(dT)8 covalently attached to an azidoproflavine derivative can bind to 
a d(T)8-d(A)8 sequence of a double helix. When irradiated with light of 
wavelengths longer than 300 nm, crosslinks are induced through the 
azidoproflavine moiety.  Subsequent treatment of this crosslinked complex 
with piperidine results in cleavage at the site of the crosslink.  Analysis of 
the cleavage patern showed that the [a]-(dT)8 oligonucleotide is oriented 
parallel to the d(A)8 strand of the Watson-Crick duplex.  This suggests the 
formation of reverse Hoogsteen hydrogen bonding between thymine of the 
a-oligomer and adenine of the T base pairs.  Investigation of a mixed 
sequence (C/T) a-oligonucleotide57 showed it to bind anti-parallel to the 
purine strand of the target duplex.  Protonated cytosine is not capable of 
forming reverse Hoogsteen complexes strictly analogous to those formed by 
thymine (figure 14).  The pseudo-reverse Hoogsteen hydrogen bonding 
scheme envisioned for C+ would place the glycosidic bond in a different 21 
position relative to that in the reverse Hoogsteen hydrogen bonding scheme 
of thymine making them incompatable. 
Methylphosphonates (figure 15) have been widely investigated for use 
in the antisense field. These analogues are nonionic, which is believed to aid 
cell permeability, and resistant to nucleases.  Initial studies58 with adenine 
dimers containing methyl-phosphonate linkages showed 2:1 complex 
formation with polymers of T or U. Later studies59 with nineteenmers of 
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Figure 14. Reverse Hoogsteen TAT triplet (above) and C+GC pseudo-reverse 
Hoogsteen triplet. 22 
methylphosphonate oligomers (dA*19, dr`19 or dU*19) failed to show any 
triplex  formation whether  targeted  against  duplexes  containing 
phosphodiester linkages or a phosphodiester-methylphosphonate hybrid 
duplex.  Callahan et al.60 later showed that d(CT)8 oligomers containing 
methylphosphonate linkages do form a 2:1  complex with d(GA)8 
phosphodiester strands. The apparent pka for this complex is reported to be 
4.5, while that of the analogous all-phosphodiester triplex is 5.6. The loss of 
favorable electrostatic interactions between protonated cytosines and the 
negatively charged backbone is believed to be responsible for this. 
Preliminary studies of a triplex containing only one methylphosphonate 
strand (in the Hoogsteen position) indicate an apparent pka of 5.4. 
Phosphorothioates (figure 15) have also been widely investigated in 
terms of antisense applications.  Latimer at al.61 investigated triplex 
formation of phosphorothioate containing polymers (poly(dsA), poly(dsT), 
poly(dsGdsA),  poly(dsCdsT))  with  polymers  containing  natural 
phosphodiester linkages or phosphorothioate linkages. They reported that 
modificaton 5' to a purine promotes triplex formation whereas modification 5' 
to a pyrimidine destablizes triplexes. This may be due to steric or electrostatic 
repulsion between the sulfurs of the two pyrimidine strands.  Nuclease 
resistance of these analogues also gave confusing results.  For example, 
poly[d(sAsT)]  is  essentially resistant to cleavage by DNase  I  while 
poly[d(AsT)] has a half-life of 30 minutes.  On the other hand, both 
poly[d(sAT)] and poly[d(AT)] have half lives of less than one minute. 
A recent study by Matteucci at al.62 did a side by side comparison of 
triplex formation with third strands containing the natural phosphodiester 
linkages, methylphosphonate linkages, (methoxyethyl)phosphoramidite 23 
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Figure 15. Backbone analogues. 24 
linkages and formacetal or 5'-thioformacetal linkages (figure 15).  The 
control phosphodiester showed protection of the target duplex from DNase I 
cleavage at 1µM concentration, the formacetal linked oligomer performed 
similarly.  The methylphosphonate linked oligomer required greater than 
1011M concentration to give similar protection.  Both the (methoxyethyl)­
phosphoramidite and thioformacetal linked oligomers behaved worse than 
the methylphosphonate oligomers. 
Recently an oligonucleotide analogue was designed that contained a 
peptide backbone in place of the sugar-phosphate backbone63,64 (figurel5). 
When these compounds were tested for triple helix formation against a 
dA 0-dTi0 tract, it was found that the mode of binding was not triple helix 
formation, but strand displacement. These peptide nucleic acids (PNAs) were 
found to form very stable PNA-DNA double stranded complexes (Tm=73°C as 
compared to 23C for a dAiodTio duplex). The strand displacement model was 
verified by demonstrating increased sensitivity of the displaced dT 
segment to the nuclease Si (which is single strand specific) and to oxidation 
by potassium permanganate.  Interestingly, these authors state that this 
strand displacement mode of binding may be a general principle for 
oligonucleotide analogues containing neutral backbones. 
Despite the aforementioned problems with triple helix formation, 
many successful applications have been reported.  Maher et a/.41 
demonstrated that oligomers 20-21 by long protect an underlying 
complementary sequence of a recombinant plasmid from cleavage by the 
endonuclease Ava I,  as well as from methylation by M. Taq I (which 
methylates N6 of adenine residues in the sequence 5'-TCGA thus preventing 
cleavage by the endonuclease Taq I at that site).  Oligonucleotides containing 25 
5-methylcytosine conferred protection at lower concentrations than 
oligonucleotides containing cytosine.  An A/G containing oligonucleotide 
failed to demonstrate protection at any concentration studied. These authors 
postulate that the GGC and AAT binding motifs are mutually incompatible. 
Purine rich oligonucleotides, despite the initial confusion concerning 
strand orientation and base pair specificity have proven useful in GGC and 
TAT (reverse Hoogsteen) contexts due in part to their pH insensitivity. 
Oligomers using this binding motif have been shown to repress transcription 
of the human c-myc gene' in vitro. Durland et a1.65 demonstrated binding 
of G/T containing oligomers to sites in gene promoters as evidenced by DNase 
I footprinting analysis.  Triple helix formation utilizing this motif was also 
shown to reduce c-myc m-RNA levels in vivo66.  This study monitored 
triplex-mediated transcription arrest in HeLa cells, and found a 10-fold 
reduction of c-myc steady state mRNA. This study also investigated the 
uptake of oligonucleotides by cells and found that uptake reached a steady 
state after 2h. Oligonucleotide was shown to concentrate in both the nucleus 
and the cytoplasm and to be stable for 4h. 
Several other examples have appeared67-71 which demonstrate either 
inhibition of transcription or of restriction enzyme cleavage most often 
using the pyrimidine-purine-pyrimidine motif. One study using an oligomer 
containing the protonated cytosine analogue N6-methyl-8-oxo-2'­
deoxyadenosine (MODA) reported inhibition of transcription elongation in 
vitro72.  Oligomers containing both MODA and T targeted against a G/A 
containing sequence were shown to form triple helices and to prevent RNA 
polymerase II-mediated transcription in vitro.  It was also discovered that 
after thirty minutes most of the truncated transcripts were converted to full 
length indicating that a stalled polymerase complex mediates triple helix 26 
dissociation. MODA containing oligomers having a C* (figure 16) at the 3' 
end demonstrated that triple helices prevented from dissociating (through 
covalent attachment of the third strand to the purine strand of the target 
duplex) could effectively prevent transcription elongation even after 
prolonged treatment. 
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Figure 16. N4,N4-ethanocytosine (C*). 
The fact that minor groove binding agents such as the aforementioned 
netropsin and distamycin molecules are nearly isohelical with B-form DNA 
could allow them or molecules closely related to them to serve as neutral, 
rigid supports for natural or unnatural nucleobases capable of forming base 
triplets.  These molecules, being more rigid than the sugar-phosphate 
structures of nucleic acids, would be prearranged for binding to a double 
stranded B-form DNA target, possibly resulting in more favorable kinetics, 
avoiding a B to A (or A') transition either prior to or concurrent with triplex 
formation. 
In order to design a platform which would allow B-form triplex 
formation, the longer distance around the B-form duplex must be considered. 
The natural sugar-phosphate backbone conforms well to A-form DNA, but is 
too short to complex to DNA in the B-form. The distance between adjacent 
steps in an A-form DNA duplex is 5.4 A, while that in a B-form duplex is 
approximately 7 A. Goodsell and Dickerson73 addressed the phasing problem 27 
of molecules like distamycin by replacing the pyrrole ring with other 
aromatic rings or the amide linkages with other linkages.  Helical 
parameters of computer generated polymers of a selected monomer were 
then compared to those of B-form DNA. Utilizing a very similar process, a 
computer search for a backbone having helical parameters that matched 
those of B-form DNA has been undertaken. 
Molecules composed of heterocyclic rings connected through amide 
linkages similar to the netropsin / distamycin structures were considered as 
backbone types. By attaching recognition moieties similar or identical to the 
nucleic acid bases (G, C, A, T/U), these structures then become nucleic acid 
analogues (figure 17).  It is hypothesized that, due to the rigidity of the 
backbone, the analogue would have a higher affinity for its target than 
would a deoxyribose derived backbone and would also be less tolerant of 
mispairs. By varying the heterocycle, the helical parameters and lengths of 
these backbones could be tailored.  In addition, carbon-carbon double bonds 
could be inserted between the heterocycle and the amide group to add length 
to the analogue.  This would be necessary to span the greater distances 
required for triplex formation in the B-form. 
Figure 17. Proposed backbone types. (B=nucleic acid base). 28 
In addition, an investigation of the use of two novel bases for triple 
helix formation has been undertaken. One distinguishing feature of the two 
defined motifs of triplex is the placement of the backbone of the third strand 
within the major groove of the duplex. In the pyrimidinepurinepyrimidine 
triplex the backbone of the third strand is located toward the purine side of 
the  major  groove  while  that  of  the  third  strand  in  the 
purinepurinepyrimidine triplex is situated more toward the middle of the 
groove.  We proposed the use of the base 7-deazaadenine (7dA) in the 
protonated form in place of protonated cytosine in a C+-GC triplet and 
hypoxanthine in place of thymine in the Hoogsteen position of a TAT triplet 
(Hoogsteen II (HII) pairing, figure 18). A study by DeClercq24 reporting 
triple helix formation between a poly(T)poly(rA) duplex and poly(rI) 
strands led us to the choice of hypoxanthine (the base of the nucleoside 
inosine).  The higher pka of 7-deazaadenosine (5.3) as compared to cytidine 
led us to the choice of this base in hopes of improving the pH dependence of 
triple helix formation with CG containing targets. The backbone in a helix 
containing IAT and 7dAGC triplets is again in a different position.  It is 
nearer to  the center of the major groove, as compared to  the 
pyrimidinepurine pyrimidine triplex, which would provide greater access 
to all hydrogen-bond donors/acceptors of the Watson-Crick base pair.  It was 
hoped that repositioning of the backbone (figure 19) would provide a 
gateway to the design of analogues capable of specific recognition of all four 
Watson-Crick base pair arrangements. 29 
Figure 18. IAT (left) and 7dA+GC triplets. 
( C1' of inosine, HQ) 
( C1' of thymine, HI) 
Figure 19. Position of backbones within the major groove. 30 
RESULTS AND DISCUSSION
 
I. Molecular Modeling 
The design of a novel backbone for the third strand of a B-form DNA 
triplex was undertaken as follows. Molecules containing one or two aromatic 
(usually heterocyclic) rings and an amide, with or without a double bond in 
between, were considered as monomeric backbone units (figure 20).  A 
heterocyclic base (either thymine, to accomodate the Hoogsteen I position 
(HI), or hypoxanthine, to accomodate the Hoogsteen II position (HID) could 
be attached to these potential backbones at various sites.  In addition, the 
bases could either be attached directly to the backbone or with one 
methylene group in between.  Dimers of each potential backbone were 
constructed in which all dihedral angles were either set to 180 or 0° so as to 
produce a flat, fully extended molecule. The distances between possible base 
attachment sites in adjacent dimers were then calculated (figure 21), and 
these values then compared to the distance necessary to span two adjacent 
bases in a B-form DNA triple helical format. 
Those monomers having suitable lengths (either 6.98 A for HI, or 7.70 
A for HII) were then examined further for their ability to conform to a B-
form DNA duplex target. The coordinates of two adjacent bases of the third 
strand of a B-form triplex were generated by superimposing A-form base 
triplets23 into a B-form environment. Two atoms of the heterocyclic base 
(thymine or hypoxanthine) along with the attached ribosyl Cl' 31 
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Figure 20. Backbone analogues investigated. Arrows indicate possible base 
attachment sites. 
(representing the methylene spacer) were fixed in  space at two adjacent 
steps of the helix. Only those atoms along the backbone necessary to connect 
one C1' to the next were included in these calculations (figure 22). The bond 
length and bond angle values of the components of the subunits were taken 
from crystal structures of similar compounds74-86. The coordinates for each 
atom would be calculated using these literature values and assigned values 
for the variable torsions connecting the components (figure 22).  When the 
end of the monomeric chain was reached, the bond distance between it and 32 
the C1' attached to the second base was calculated (figure 22).  If this value 
was within 0.1 A of the accepted value then the bond angle a was calculated. 
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Figure 21. Distance calculations between adjacent base attachment sites. 
If this value was within 5° of the accepted value, this conformation would be 
saved for further processing. The variable torsions were then incremented 
in a systematic fashion in order to investigate the entire range of possible 
conformations. Amides were evaluated only as the anti isomers.  In some 
instances, the bond angle values along the backbone were varied by small 
increments (0.5° at a time up to a maximum of ±4.5°) in order to obtain a 
better fit.  It has been observed in the crystal structure of netropsin that 
bond angle values distort by as much as 4.5° from standard values74. 
Each conformer which met the criteria above was further evaluated 
by generating a hexamer with that defined conformation to determine if it 
was capable of forming a helix compatable with B-form DNA. The suitability 
of a given conformation for triplex formation ultimately came down to two 
parameters. One is the agreement of the two dihedral angles connecting the 
bases to the backbone (4) ,  figure 23), the other is the pitch angle (U) of the 
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Figure 22.  Illustration of dihedral driver program. Atoms in bold in the 
figure on the right are the only atoms used in this program as illustrated in 
the figure on the left.  Torsions about the atoms in bold are those varied. 
Bonds indicated by a dashed line and angle a are those analyzed for each 
conformer. 
helix.  The dihedral angle requirement assures the formation of a regular 
helix that would tend to remain in phase with the target helix. The 
BASE 1 
..­
Figure 23. Illustration of dihedral angles (0,left) and pitch angle (H,right). 
Reprinted with permission from ref. 73 copyright 1986 American Chemical 
Society. 34 
comparison of the pitch angle of the hexamer with that calculated for the 
third strand of a B-form DNA triplex (28.76 for Hoogsteen I; 25.86 for 
Hoogsteen II) indicates that the analogue is isohelical with the DNA target. 
Those backbones meeting the above criteria were then further 
evaluated. Using the molecular modeling program AMBER87,88, an all-atom 
hexamer with the predetermined conformation was generated.  The 
parameters for atom types not included in the program were either taken 
from similar structures (indole from tryptophan for example) or added to the 
program based upon values taken from the literature (see appendix I). 
Charges for the backbones were derived independently using the program 
Quest89 (figure 24). A triplex consisting of a (dT)6(dA)6 Watson-Crick target 
and a third strand composed of one of our new backbones carrying either 
thymine or hypoxanthine residues was then generated.  Both stands of the 
target duplex were constrained during the initial energy minimization 
process. 
The energy of the system is analyzed as a sum of strain energies and 
nonbonded interaction terms: 
&tal  'bonds Kr(r  req)2 + "anles Ko(15 beq)2 + Idihedrals1/21([1 + COS(11,Y)] 
+ 14(34/R121J) - (A11/R611) + (WERii) 
The first three terms represent the difference between a geometry in which 
the bond lengths, bond angles, and dihedral angles have ideal values and the 
actual geometry. The remaining terms represent nonbonded van der Waals 
and electrostatic interactions. 35 
Figure 24. Illustration of charge calculation. The molecule on the left was 
used to simulate the environment of the benzofuran ring in the molecule on 
the right. 
In numerous cases it was found that severe van der Waals repulsions 
existed (figure 25) between atoms not included in the previous phase of the 
modeling process. This turned out to be the case in every instance where no 
methylene spacer linking base and backbone was employed.  Occasionally, 
minor van der Waals repulsions could be translated into a small angle strain 
Nyr 
Figure 25. Severe van der Waals interactions between base and backbone
 
components.
 36 
component during the minimization process.  Nevertheless, these hexamers 
were of routinely higher energy.  Ultimately, our search led us to two 
possible backbones to target B-form DNA (figure 26).  Results indicate that 
these backbones are able to form unstrained triplexes, assuming that the 
Length:  6.758A  6.950A 
Pitch angle:  26.40 (HI)  27.50 (HI) 
4)1,4)2:  310.0, 299.4  310.0, 302.4 
Figure 26. Modeling results of two potential backbones. Lower figures 
illustrate helical conformation of trimers of the two above monomers. 37 
single bond torsions along these backbones are capable of adopting 
nonplanar conformations without undue strain, as has been seen in 
netropsin, distamycin and benzanilide90 structures. 
The values for the dihedral angles of each of the above structures are 
given in table 1.  Most of the values for each monomer are within ±50° from 
planarity, a limit cited in previous studies73. 
Table 1. Dihedral angle values for benzofuran (b-furan) and pyrrole 
monomers shown below. 
a  13  7  5  E 
b-furan  310  300  190  10  299.35 
pyrrole  310  300  190  70  70  302.388 
H 
Energy analysis of the benzofuran analogue in the HI format showed an 
interaction energy of the third strand with the purine strand of - 193.42 
kcal/mol.  This  is even more favorable than the interaction energy 
calculated for the two Watson-Crick strands (-1 1 8.2 8 kcal/mol). The same 
trend was observed for the benzofuran analogue in the HII format, an 38 
interaction energy for the third strand of -160.98 kcal/mol was found, while 
that for the Watson-Crick strands was -111.11 kcal/mol. These trends are due, 
at least in part, to hydrogen bonding interactions between phosphate 
oxygens along the backbone of the Watson-Crick purine strand and amide 
NH's along the backbone of the analogue.  Three such interactions were 
observed in both the HI and HII complexes at the 2nd, 3rd and 4th residues. 
While these interactions are nonspecific in nature, they do still stablize the 
overall structure. 
An interesting feature of these analogues is that the bases of the third 
strand do not appear to stack. This can be seen in the view of a hexamer of 
the benzofuran analogue shown in figure 27.  Both hydrogen bonding and 
stacking interactions are known to stablize a triple helix91. A triple helix 
involving the analogue 8-oxoadenine in the third strand has been observed 
without significant hypochromicity92.  Nevertheless, these triplexes were 
found to be as stable as triplexes containing 5-me-cytosine in the third 
strand. Though this lack of hyperchromicity may be due to a disruption of 
the aromaticity of the 8-oxoadenine ring system rather than a lack of base 
stacking. 39 
Figure 27. View of benzofuran analogue (HI) down the helical axis 
illustrating lack of base stacking. 40 
II. Investigation of Deoxyinosine and Deoxy-7-deazaadenosine for Triplex 
Formation 
The initial oligomer chosen for testing is shown in figure 28 (oligomer 
IV).  Francois et al, 70 has demonstrated triple helix formation with the HI 
type oligomer 5'-I-1-1-1-1-ICTTCTCTTTCC (oligomer III).  Oligomer IV is the HI! 
counterpart of this oligomer.  The HI strand was also shown to inhibit 
cleavage of a complementary dsDNA target by restriction endonuclease KSP 
6321.  It was felt that the HI oligomer could serve as a positive control in this 
or other assays.  Extension of the target duplex sequence (HI, figure 28) 
beyond the triple helix forming region by 6 GC base pairs at both the 3' and 
5' ends ensures a stable duplex.  Without such "sticky ends", one could 
envision mechanisms of interaction other than the expected triple helix 
formation.  With the HI! strand, the possibilities are limited due to the 
absence of a hydrogen bond acceptor site at the 7 positon of 7dA. 
Oligodeoxynucleotides containing 7dA and deoxyinosine were 
synthesized by the phosphoramidite approach. While the 5'-dimethoxytrityl 
protected phosphoramidite of 2'-deoxyinosine is commercially available, that 
of 2'- deoxytubercidin (7dA) was prepared following literature procedures93. 
These monomers were then submitted for solid phase synthesis of the desired 
oligomer. 
Solid phase synthesis of deoxyribooligonucleotides starts from the 3' 
end of the oligomer.  Due to the fact that our chosen sequence has a 2'­
deoxytubericidin residue at the 3' end, synthesis of the hemisuccinate (figure 41 
I: 5'-GCGCGCCCTTTCTCTTCIT1111CCCCCC-3' 
II: St-GGGGGGAAAAAAGAAGAGAAAGGGCGCGC-3' 
III: 5'-1111I1CTTCTCMCC-3' 
IV: 51-IIIIIIA*IIA*IA*IIIA*A*-3' 
Figure 28. Oligonucleotides used in testing experiments. 
(G=deoxyguanosine, C.deoxycytidine, T=thymidine, A=deoxyadenosine, 
I=deoxyinosine, A*=deoxy-7-deazaadenosine) 
29) was necessary93f. This compound is needed to attach the nucleotide to the 
column support material (which was performed by Peninsula Labs) used in 
the solid phase synthesis process.  Columns containing the common 
nucleosides (dT, dC, dG, dA) are commercially available. 
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Figure 29. Hemisuccinate of 7dA.
 
After an oligomer has been synthesized by solid phase, it is cleaved 
from the solid support and treated with NH3 to remove benzoyl protecting 42 
groups of A and C residues, giving benzamide as a by-product, and isobutyl 
protecting groups from G residues.  Oligomers obtained by solid phase 
synthesis were purified first by extraction with diethyl ether of an aqueous 
solution of the material obtained in order to remove the by-products of the 
deprotection procedure. Residual ether is then removed from the remaining 
aqueous solution under reduced pressure. The aqueous solution contains not 
only the desired oligomer but also shorter fragments resulting from failed 
coupling reactions.  These oligomers are separated on the basis of charge 
using ion exchange chromatography.  Each oligomer has one negative 
charge per phosphate residue, in addition, conditions can be employed which 
further ionize the oligomers.  High pH (10.5) conditions were utilized in 
order to deprotonate T (at N3), G (at N1) or I (at N1) residues. 
An aqueous solution of the crude oligonucleotide was applied to a Q. 
Sepharose column. Elution solvents consisted of 0.05 M CH3NH2 (aq) pH 10.5 
(solvent A) and 1 M KCI, 0.05 M CH3NH2 (aq) pH 10.5 (solvent B).  Starting 
conditions were 70% A, 30% B.  Solvent ratio was adjusted to 100% B over a 
period of 1 h at a flow rate of 2 mlmin.  Fractions were collected and 
monitored by UV at 258 nm (figure 30). Those fractions containing the latest 
eluting (most highly charged) species were combined. This solution was 
desalted (figure 30) by reverse phase chromatography on polypropylene 
(Me0H/H20/NH4OH, 160:80:1). 
UV melting curves were used to investigate triple helix formation. 
When two strands of DNA (or RNA) bind to form a double helix there is a 
decrease in the intensity of the UV absorbance (hypochromic shift) relative 
to the sum of the absorption of their constituent nucleotides due to base 43 
Figure 30. Purification (left) and desalting (right) of oligomer II. 44 
stacking interactions94.  If the temperature of a solution containing a double 
helix is slowly raised, a sharp increase in the UV will be observed at a 
specific temperature referred to as the melting temperature (Tm).  This 
hyperchromic shift is indicative of the helix unwinding. The narrower the 
temperature range over which a helix unwinds, the more cooperatively it is 
said to "melt".  In the case of triple helices, biphasic melting curves are 
usually observed. The first lower temperature transition corresponds to the 
dissociation of the Hoogsteen strand from the Watson-Crick duplex while the 
second transition corresponds to the melting of the duplex. This is generally 
verified by comparing melts of the triplex to those of the duplex in the 
absence of the third strand. 
UV melts of the aforementioned oligomers were initially carried out in 
10 mM sodium cacodylate (pH 6), 100 mM NaCl, 0.5 mM spermine with 
oligomers at 1.5 RM each. Under these conditions, only the duplex melt was 
observed for both the positive control (HI) and the test system (HII).  Triple 
helices are known to be stablized by high salt concentration, particularly 
multivalent ions such as Mg++. The above conditions were modified by 
increasing the concentration of the oligomers to 3µM and by the addition of 
MgC12 (50 mM). Under these conditions, triplex formation for the positive 
control system was observed, with a Tm for the third strand of 52°C, and that 
of the Watson-Crick duplex at 79°C (figure 31). This is seen more clearly in 
the first derivative plot (figure 32). The test system however continued to 
show evidence of only duplex formation (figure 33). While the use of 7dA 
was intended to improve the pH dependence of triplex formation, the pH was 
lowered to 5 in hopes of observing triplex formation. The results however, 
(figure 34) were discouraging. 45 
Due to DeClercq's work, it had been assumed that deoxyinosine would 
form a stable base triplet with dAdT base pairs.  It was decided however, to 
investigate dI alone and verify this hypothesis. New oligomers were 
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Figure 31. UV melting curves of oligomers VII /III (upper curve) and 
oligomers VII (lower curve). 
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Figure 32. First derivative of triplex melt. 46 
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Figure 33. UV melting curves of oligomers 1/11/IV (upper curve), and 
oligomers I/II (lower curve). 
2.50 
2.4 
-zis
In 
(NI  2.30 
2.20 
2.10 
0  10 20  30 40 50 60 70 80 90 100
 
T( C) 
Figure 34. UV melting curve of oligomers I/II/IV at pH 5. 47 
synthesized (figure 35) and purified as described above. UV melting curve 
experiments were carried out under the same conditions mentioned above 
except at pH 7. The control (oligomer VII) showed a clear biphasic melting 
curve (figure 36) with a Tm of 56°C for the Hoogsteen strand and a Tm of 78°C 
for the Watson-Crick duplex.  The test system again failed to show any 
evidence of triplex formation by this method (figure 37). 
V: 5'-GCGCGCAAAAAAAAAAAAAAAAACCGGCC-3' 
VI: 5'-GGCCGG11 1-1-1-1T1T1-1-11-11-1TGCGCGC-3' 
VII: 5'-11111111111111111-3' 
VIII: 
Figure 35. New oligomers synthesized to test dI binding. 
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Figure 36. UV melting curves of oligomers V/VI/VII (upper curve) and of 
oligomers V/VI (lower curve). 48 
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Figure 37. UV melting curves of oligomers V/VI/VIII (upper curve) and of 
oligomers V/VI (lower curve). 
An additional method used to monitor triplex formation is gel mobility 
shift assays95. This technique has long been used to study protein-DNA 
interactions96.  The mobility of a protein-DNA complex through a non-
denaturing polyacrylamide gel is retarded relative to that of the DNA alone. 
While a DNA triple helix is believed to be approximately the same size as a 
DNA double helix, with the third strand fitting snugly within the major 
groove, the electrostatic nature of each is believed to be different resulting 
in differing mobility of a double strand as compared to a triple strand. 
Investigation of the control using this technique resulted in the gel 
shown in figure 38. Lanes 1, 2 and 3 contain the pyrimidine strand of the 
target duplex, the purine strand of the target duplex and the third strand 
respectively. Lanes 4 and 5 contain the duplex and triplex respectively. The 49 
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Figure 38. Gel mobility shift assay of oligomers V/VI/VII 
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Figure 39. Gel mobility shift assay of oligomers V/VI/VIII 50 
latter two lanes show the retarded mobility of the triplex relative to the 
duplex. Investigation of the test system by this technique resulted in the gel 
shown in figure 39. Lanes 1 and 2 are the same as for the positive test system 
while lane 3 contains the d(I)17 strand. Lane 4 is also the same as for the 
positive test system while lane 5 contains the target duplex plus d(I)17. The 
slower eluting band in lane 5 comigrates with the duplex (lane 4) while the 
faster eluting band of lane 5 comigrates with d(I)17 (lane 3) indicating no 
interaction between the duplex and d(I)17. 
This was further investigated by removing the band believed to be the 
duplex from lane 5 and isolating the DNA contained therein by the crush and 
soak method97. This material was hydrolyzed with a combination of snake 
venom phosphodiesterase I and alkaline phosphatase to the constituent 
nucleosides which were subjected to HPLC analysis (figure 40).  By 
comparison with authentic samples, the absence of dI was shown.  This 
further verified the absence of any interaction between d(I)17 and the 
target duplex. 
The integrity of both the d(I)17 and the oligomer IV were further 
investigated to rule out any question of their ability to bind to the target 
duplexes. The d(I)17 strand showed the expected UV melting curve (figure 
41) with a seventeenmer of dC.  Also, both the d(I)17 and the oligomer IV 
were seperately subjected to enzymatic hydrolysis and HPLC analysis (figure 
42).  By comparison with authentic samples, each oligomer was shown to 
contain only the expected nucleosides. 
These results indicate that short oligomers containing dI and d7dA are 
unsuitable for use in third strands of triple helices. The reported examples of 
triplex formation with inosine have involved polymers as opposed to 
oligomers.  Some studies have shown unusual length requirements when 51 
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Figure 40. Hydrolysate of DNA from gel, (A). dG/dC/dA/dT standard, (B); 
coinjection of A and B, (C); coinjection of A and d(I), (D). 52 
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Figure 41. UV melting curve of d(I)17d(C)17 
dealing with nonstandard base triplets such as poly(rA)-poly(rA)poly(rU)9 8 
and poly(rA)poly(rG) poly(rC)99. In addition, it is not known whether the 
nature of the backbone has any effect on triplex formation in this case. The 
poly(rI)poly(rA)-poly(T) triplex reported by DeClercq contains two ribose 
backbones and one deoxyribose backbone.  The presence of one or more 
ribose backbones in the complex may be necessary.  It has been reported that 
triple helices containing oligo (2'- O- methyl)ribonucleotides are more stable 
than oligomers of DNA100.  It remains to be seen whether dI and 7dA could 
form stable base triplets if paired with a backbone analogue or a (2'-0­
methyl)ribose backbone. 53 
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Figure 42. Hydrolysates of oligomers IV and VIII. (A) hydrolysate of 
oligomer IV; (B) d(I)/d(7dA) standard; (C) coinjection of hydrolysate of 
oligomer IV and d(I)/d(7dA) standard; (D) hydrolysate of oligomer VIII; 
(E) d(I) standard. 54 
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Figure 42. Continued. 55 
III. Synthesis of Nucleoside Analogues 
Synthetic studies of the benzofuran backbone discovered through the 
modeling studies focused initially on the bromomethylbenzofuran (7). This 
compound would serve as a key intermediate in the synthesis of various 
monomeric units. Alkylation of this compound could be accomplished with a 
variety of heterocyclic bases or precursors to heterocyclic bases at a late 
stage in the synthesis of various monomers. 
The synthesis of compound 7 is outlined in scheme 1. A Wittig reaction 
between o-hydroxyacetophenone (1) and the phosphorane (2) made from 
ethyl  bromoacetate and triphenylphosphinel 0 1 ,  followed by an 
intramolecular ring closure in refluxing toluene gave  4-methylcoumarin102 
(3) in 91% yield. This compound then needed to be functionalized at both the 
3 position in order to facilitate a ring  contraction103 and the 5 position 
which would later serve as the amine component of the amide linkages. 
Nitration is preferable at this stage rather than at the benzofuran stage due 
to the reported poor selectivity of this ring  system104. The reactivity of the 
coumarin ring system at both the 3 and 6 positions toward electrophiles make 
this a more challenging prospect than it would first seem.  It has been 
reported that in order to obtain mononitro compounds of coumarins, the 
theoretical amount of nitric acid must be employed105, in addition, alkylation 
of coumarins increases the ease of nitration.  The most favorable results 
obtained were a 9:1 mixture of the 6-nitro and 3,6-dinitro products (91% 
combined yield), which could not be separated. 56 
As an alternative, prior bromination at C-3 was considered. Coumarins 
add bromine to give the 3,4- dibromides which easily lose HBr resulting in the 
3-bromocoumarin. Alkylation at the 4 postion is rep6rted to destablize the 
toluene 
Ph3P=CHCO2Et 
ex 
2  3 
HNO3 /H2SO4  02N  Br2  02N 
4  5 
NaOMe 
02N 
NBS 
02N 
Me0H,  0 
CO2Me  140°C  CO2Me 
6  7 
Scheme 1 
dibromide105. Initial bromination of 3 provided the 3-bromo product though 
some bromination of the benzene ring was also observed.  Unfortunately, 
nitration of the 3-bromo compound resulted in the formation of the 3-bromo­
6-nitro product as well as some 6-nitro product indicating that the 
bromination is reversible under the acidic conditions of the nitration 
reaction. This mixture of products was again inseparable. 
Finally, it was found that pure 4 could be obtained by quenching the 
nitration reaction of 3 prior to completion. Since the 6 position reacts faster 57 
than the 3 position, this resulted in a mixture of the desired 6-nitro product 
and the starting coumarin. Trituration of this mixture with CHCI3 removed 
unreacted starting material which could be recovered for later use. 
Recrystallization of the remaining solid gave pure 4 in 66% overall yield. 
Bromination of the 3 position was then easily accomplished with neat 
bromine in 94% yield. Treatment of 5 with NaOMe in Me0H affected a ring 
contraction103 of the coumarin to the benzofuran (6) in 77% yield. Benzylic 
bromination106 of the 4-methyl group of 6 with N-bromosuccinimide  gave 7 
in 68% yield after recrystallization from Me0H. 
At this junction, the feasibility of joining these moieties together to 
form amide linked oligomers was investigated. Compound 6 was converted to 
the corresponding carboxylic acid in 95% yield by treatment with aqueous 
NaOH (scheme 2). Compound 6 was also separately converted to the 
02N  02N 
NaOH (aq) 
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H2 (40 psi) 
2-cbloro- 1 ­
methylpyridini urn 
iodide, HOBt, CH2Cl2 
H2N 
OCH3 
02N 
O 
9  10 
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02N 
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Scheme 2 58 
corresponding amine in 99% yield by catalytic reduction.  Following 
procedures enlisted in the synthesis of distamycin analogues107, compound 8 
was converted to the HOBt ester using 2-chloro-l-methylpyridinium iodide. 
Reaction between the crude ester 10 and the amine 9 gave the desired amide 
(11) in 50% yield. 
Compound 7 can now serve as the starting point for the synthesis of 
numerous nucleoside analogues.  For example, alkylation of cytosine108 by 
reaction between the anion of cytosine and compound 7 resulted in the 
formation of 13 in 79% yield (scheme 3).  This compound could serve as the 
Hoogsteen I component of a C+GC base triplet. The other analogue desired to 
go along with the cytosine compound was the corresponding uracil or 
thymine compound.  While direct alkylation with either uracil or thymine 
led to inseparable mixtures of the 1- and 3-alkylated products, 13 could be 
NH2 
N  1-BuOK, DMSO 02N  + 
N  0  CO2CH3 
H 
12  7 
02N 
13  14 
Scheme 3 59 
transformed into the uracil analogue109 through a nitrosation reaction. 
Treatment of 13 with sodium nitrite in a mixture of trifluoroacetic 
acid/acetic acid gave the desired uracil analogue (14) in 69% yield.  This 
compound could serve as the Hoogsteen I component of a UAT base triplet. 
The other set of desired compounds were the Hoogsteen II analogues 
containing hypoxanthine or 7-deazaadenine.  Toward this  end,  6­
chloropurine (15) could be alkylated with 7 (scheme 4) in the same fashion 
as for cytosine leading to 16 in 80% yield. The 6-chloropurine ring could be 
converted to  the hypoxanthine ring system by treatment with  2­
pyridinealdoxime110 in the presence of tetramethylguanidine. This resulted 
in the formation of compound 17 in 79% yield. This compound could serve as 
the Hoogsteen II component of an H -AT base triplet. 
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Scheme 4 60 
Finally, the 7-deazaadenine analogue could be obtained through 
alkylation of 6-chloro-7-deazapurine93 with compound 7 resulting in a 52% 
yield of 19 (scheme 5).  This compound was converted to the azide in 90% 
yield by treatment with sodium azide in DMSO. Compounds such as these can 
be  converted  to  the  phosphinimines  by  treatment  with 
triphenylphosphine111.  It has been reported that phosphinimines derived 
from simple alkylazides are readily hydrolyzed to the amines and 
triphenylphosphine oxide on exposure to moisture" 2.  Phosphinimines 
derived from 5`-azido-5'-deox-ythymidine however, have been reported to be 
relatively stable in water but hydrolyze cleanly to the aminonucleosides on 
treatment with ammonium hydroxide113. Treatment of the phosphinimine 
derived from the azide of 19 with water or ammonium hydroxide failed to 
Cl 
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CO2Me 
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Scheme 5 61 
provide any of the desired amine. An alternative method for converting 
azides to amines is treatment with HBr in acetic acid. This reaction must be 
carried out in the presence of phenol as a Br2 scavenger114. This procedure 
provided the desired 6-amino-7-deazapurine ring system in 85% yield.  This 
analogue serves as the Hoogsteen II component of a 7dA+GC base triplet. 
While this would constitute the synthesis of each desired nucleoside 
analogue, each of these compounds suffered to some degree from insolubility 
in most common organic solvents.  Essentially, only DMSO or DMF could be 
used  as  reaction  solvents  and  standard  purification  methods 
(chromatography, recrystallization) were generally unsuccessful.  In 
addition, the solubility of oligomers of these compounds in water, even with a 
terminal polyethylene glycol tail115, was doubtful. Therefore, synthesis of 
compounds containing small, water solublizing groups on each residue was 
considered. Inspection of conformers from the modeling study indicated that 
both the 7-position of the benzofuran ring or the 5-position of a pyrimidine 
ring would easily bear substitution without interfering with the hydrogen 
bonding of the analogue to its target.  Due to the ready availability of 5­
substituted pyrimidine ring systems, synthesis of compound 24 was 
undertaken. The glycol methyl ether tail was attached to the 5 position of 
compound 21116 in 50% yield (scheme 6) using a modification of a procedure 
used to attach benzyl ether groups at that position116c. 
Alkylation of 22 with 7 (scheme 6) provided the desired product in 
only 38% yield.  The solubility properties of this compound relative to 
previous analogues was greatly improved however.  Protection of the 4­
amino group of 22 with a benzoyl group prior to alkylation improved the 62 
yield of the alkylation reaction to 87%.  Various attempts at converting 
different cytosine compounds to the thymine derivatives failed. Therefore, 
NH2 
HOH2C  CH3(OCH2CH2)30CH2
N  CH3(OCH2CH2)30H, HCl 
I 00°C 
H
 
21 
NHBz 
C HOC H2CH 2)30012 
B zCI, pyridine  7, z-BuOK, DMSO 
NAO 
23 
NHBz 
N
 
24 
Scheme 6 
5-hydroxymethyluracil was obtained from uracil  via formaldehyde 
addition117, and the same glycol methyl ether tail attached as for the 
cytosine analogue.  Alkylation of 26 with 7 provided two products which 
could be separated by flash chromatography (scheme 7).  Initially it was 
assumed that these compounds were the 1 and 3 alkylation products. Mass 
spectral and 1H NMR analysis showed however that the two compounds were 
the desired 1-alkylation product and the 1,3-bisalkylated product. Only 30% 63 
of the desired compound was obtained. This was improved to 50% by using a 
2:1 ratio of 26:7. 
The identity of 27 was further investigated using NOE (figure 43). The 
identity of 27 as the 1-alkylation product rather than the 3-alkylation 
HOH2C  H  CH3(OCH2CH2)30CH2
CH3(OCH2CH2)30H, HO 
N  100°C 
1 
H 
25 
+ 
27 
28 
Scheme 7 
product was suspected due to the fact that the C6 proton was a singlet in the 
1H NMR. Splitting of this proton by an adjacent NH would be expected as seen 
for compound 17. Upon irradiation of the protons of the methylene group 
connecting the benzofuran ring to the pyrimidine ring, a 12% NOE was 64 
observed for the C6 proton of the pyrimidine ring as well as a 9% NOE for the 
C4 proton of the benzofuran ring.  All of these observations strongly support 
the 1-pyrimidinyl structure as opposed to the 3-pyrimidinyl compound. 
CH3(OCH2CH2)30C H2 
12% NOE,., 
H 
9% NOE- H 
02N 
CO2C H3 
Figure 43. NOE results for compound 27. 
In order to be able to investigate the formation of oligomers 
containing these analogues, the nitro groups of either compound 24, or 
compound 27 needed to be converted to amino groups for future amide 
formation. Conversion of the nitro group of compound 24 to an amino group 
was accomplished in 75% yield by catalytic reduction (scheme 8).  Various 
protecting groups for the resulting amine were then investigated.  The 
optimal protecting group needed to be stable to conditions of futher reactions 
(conversion of the methyl ester to the carboxylic acid), be removed easily 
and in high yield.  Initial attempts at protecting the amino group of 
compound 9 with a BOC led to the formation of urea 32 (scheme 9). Conditions 
were eventually worked out which disfavored this product and gave 
exclusively the desired compound. Protection of the amino group of 29 was 65 
similarly accomplished in 97% yield (scheme 8).  Other protecting groups 
which were investigated for compound 29 include FMOC (59% yield of the 
protected amine), and formyl groups (56% yield of the protected amine). 
NHBz  NHBz 
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The next necessary transformation after protection of the amino 
group was conversion of the methyl ester to the carboxylic acid.  Hydroylysis 
under basic conditions for the cytosine analogue was not considered due to 
the presence of the benzoyl protecting group on the 4-position of the 
pyrimidine ring.  Cleavage of methyl esters with nucleophiles such as r has 
been reported as a particularly mild method of ester cleavagel 18. Attempts at 66 
this transformation in refluxing DMF of either the BOC protected amino ester 
or the FMOC protected compound resulted in loss of the protecting groups. 
Ester cleavage of the formyl protected compound under these conditions was 
successful (67% yield), but concern over the ease of removing this 
protecting group resulted in abandoning this prospect.  It was discovered 
however, that ester cleavage of the BOC protected compound (30) with Lit in 
refluxing pyridine could provide the desired product (31) in 51% yield. 
H2N 
BOC20, CH2C11, 
CO2CH3  H3CO2C 
CO2CH3 
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Scheme 9 
Similar transformations of the thymine analogue were  also 
accomplished (scheme 10).  Reduction of the nitro group was accomplished 
using SnC12.2H20/HC1 rather than by catalytic reduction. This analogue was 
not soluble in the solvent used for the catalytic reduction of the nitro group 
of the cytosine analogue, and use of other solvents (DMF) resulted in poor 
yields of the desired amine.  The stannous chloride procedure gave the 
desired amine in 62% yield.  Investigation of the trityl protecting group for 
the amine of this analogue resulted in the formation of the desired trityl 
amine (86% yield). However, attempts at hydrolyzing the methyl ester to the 
carboxylic acid showed that the trityl group was very acid sensitive.  Acidic 
work-up of the hydrolysis reaction resulted in a mixture of amino acid and 
tritylated amino acid. Protection of the amino group with a BOC group as for 67 
the cytosine analogue gave the desired BOC amino ester in 98% yield. Without 
the concern for base sensitive protecting groups, the methyl ester of this 
compound could be converted to the carboxylic acid in refluxing aqueous 
NaOH in 62% yield (scheme 10). 
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Preliminary investigations of the coupling of two cytosine containing 
monomers have given the desired dimer, although in moderate yields 
(scheme 11). The method used to form compound 11 failed to provide any of 
the desired amide, therefore the use of DCC/HOBt119 to form the active ester 
was investigated.  It was found that by using two equivalents of DCC, amide 
could be obtained in 50% yield. This yield is based upon the amine, with a 2:1 68 
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Scheme 11 69 
ratio of acid to amine being employed. Unreacted acid could be recovered for 
later use. 
It has been reported119 that use of a tertiary amine in the coupling 
step of reactions employing DCC/HOBt as activating agents improves coupling 
efficiency.  The  yield  of amide dropped  to  15% when  the 
diisopropylethylamine was omitted (2, scheme 11). This same study reported 
that the use of CH2C12 in the activation step followed by a mixture of 
CH2C12/DMF in the coupling step provided the best results. The addition of 
the polar aprotic solvent DMF decreases inter- and intramolecular hydrogen 
bonding as does the addition of the tertiary amine, increasing the amino 
group accessibility.  However, comparable yield of the desired dimer was 
obtained when both the preactivation and coupling steps were carried out in 
DMF (3, scheme 11).  Methods employed with much success in distamycin 
syntheses120 (4,5, scheme 11) gave lower yields of the desired amide. 
A recent comparison of carbodiimide/HOBt coupling to those using 
benztriazol-1-yl-oxy-tris(dimethylamino)-phosphonium  hexafluoro 
phosphate (BOP); benztriazol-1-y1-1,1,3,3-tetramethyluronium tetrafluoro 
borate (TBTU) or pentaflurophenol/HOBt revealed that all methods, which are 
commonly employed in peptide synthesis, are similar in overall efficiency. 
Each of these methods involves the formation of the same HOBt ester as the 
active intermediate.  In addition, no difference was found in the coupling 
efficiency with the use of DCC as opposed to other carbodiimide reagents. 
This study was carried out using standard amino acids, therefore, these 
observations may not hold true for our compounds. 
It has been reported, in work done on the synthesis of distamycin120, 
that esters formed with HOSu (N-hydroxysuccinamide) were not reactive 
enough to acylate the amino-pyrroles. The amino benzofurans in this study 70 
are also aromatic amines, making them weaker bases and nucleophiles as 
compared to aliphatic amines.  Evidence of this was seen in the slow 
formation of the BOC-amines. 
Evidence of steric crowding around the carboxyl group of these 
analogues has also been observed.  Attempts at esterifying the carboxylic 
acid of 17 were only successful using DDM121 (diazodiphenylmethane). 
Attempts at standard Fischer esterification were unsuccessful. Reagents such 
as DDM react with the carboxylate oxygen, while methods such as Fischer 
esterification involve attack at the carbonyl carbon.  Failure of the Fischer 
reaction possibly indicates the inability of a nucleophile to gain access to the 
carbonyl carbon. 
It has become apparent that a more indepth study of the coupling of 
these monomers will have to be undertaken in order to obtain an oligomer of 
the desired length.  Solid phase synthesis would be preferable to solution 
phase, but coupling efficiencies would need to be much higher than have 
been observed.  The above observations indicate that a fairly reactive 
intermediate will  be necessary in  the coupling step.  Use of a 
pentafluorophenyl ester may be suitable for example.  This intermediate 
could be formed with pentafluorophenyl trifluoroacetate122 which involves 
reaction at the carboxyl oxygen to form the initial reactive intermediate, a 
mixed anhydride. Many other activation methods have been reported in the 
literature which may warrant investigation. 71 
EXPERIMENTAL
 
A 500 A LCAA dI column, attached via a succinate ester was purchased from 
Peninsula Labs, phosphoramidites were purchased from ABI,  calf  intestine 
alkaline  phosphatase was purchased from  Amersham, and snake venom 
phosphodiesterase  I  was purchased from Pharmacia.  Concentrations  of 
single-stranded  oligodeoxyribonucleotides  were  determined  by  UV 
absorbance at 260 nm using extinction coefficients calculated by the nearest 
neighbor  method123 from the monomer and dimer values (values for dG 
were used  for  dI  in  the  calculation).  Q-Sepharose was purchased from 
Sigma. 
Methylene  chloride  (CH2C12),  pyridine,  dimethylformamide (DMF) and 
dimethyl sulfoxide (DMSO) were distilled from calcium hydride (CaH2) and 
stored over 3A/4A molecular sieves.  Methanol (MeOH) and ethanol (EtOH) 
were distilled from the corresponding magnesium alkoxides and stored over 
4 A molecular sieves.  All other reagents were purified by distillation  or 
recrystallization  prior  to  use whenever necessary.  All  moisture  sensitive 
reagents were transferred  in  a dry box  or  via  syringe under  a  positive 
pressure  of nitrogen.  All  moisture  sensitive  reactions were carried  out 
under  a  positive  pressure  of  nitrogen.  Column  chromatography  was 
performed  by  using  silica  gel  60  (Merck,  230-400  mesh  ASTM). 
Chromatography solvents were distilled  prior  to  use.  Analytical TLC was 
conducted on precoated Merck silica gel 60 F254 or J. T. Baker silica gel IB-F 
plates.  NMR spectra were obtained on an AC-300 Bruker spectrometer with 
tetramethylsilane (TMS) as  an  internal  standard.  Chemical  shifts  (8) are 72 
reported in  parts per million (ppm) downfield from TMS.  Infrared spectra 
were obtained as KBr pellets on a Nicolet 5DXB FT-IR spectrometer.  Mass 
spectra were recorded on a Kratos MSSORF or  a Varian MAT 311 mass 
spectrometer.  UV measurements were determined on an IBM 9420 UV-
Visible  spectrophotometer.  Melting  points  were determined  on  a  Buchi 
capillary melting point  apparatus and are  uncorrected. 
synthesis  of  oligodeoxyribonucleotides 
The oligos  (1 mmol) were synthesized on an ABI oligonucleotide synthesizer 
using  standard  f3-cyanoethyl  phosphoramidite  chemistry.  The  material 
obtained was initially dissolved in dI H2O (1 mL) and extracted with Et20 (3X 1 
mL).  Residual Et20 was removed under reduced pressure.  The remaining 
solution  of crude oligomer was purified by ion exchange chromatography 
on  Q-sepharose  using  a  linear  gradient  as  follows:  70% A (0.05 M 
methylamine pH 10.5), 30% B (1 M potassium chloride/0.05 M methylamine 
pH 10.5) to 100% B over 60 minutes with a flow rate of 2 mL/min.  Fractions 
containing  the  desired  oligomer were combined, desalted on a column of 
polypropylene  (washed  with  water,  30  min,  eluted  with 
water:methanol:ammonium  hydroxide,  160:80:1),  fractions  were  again 
combined,  methanol  removed  under  reduced  pressure  and  the  resulting 
solution  lyophilized. 
UV melting curves 
All experiments were carried out in 10mM sodium cacodylate, 0.1M sodium 
chloride, 50mM magnesium chloride, 0.5mM spermine, pH 5,  6,  or 7  (see 73 
text),  all oligomers were 3gM.  UV absorbance was measured once  every five 
minutes (2°C/min, 4 min hold time).  All DNA duplex solutions were heated to 
80°C and slowly cooled to room temperature prior to UV analysis. 
Gel mobility shift analysis 
Nondenaturing polyacrylamide  gel  electrophoresis was carried  out  at room 
temperature.  The  15%  polyacrylamide  gels  (29:1 
acrylamide:bis(acrylamide)] contained 90mM Tris-borate buffer (pH 8.0) and 
50mM magnesium chloride, which comprised the tank buffer  as  well.  Gels 
were run at 25 V (-10 mA) for 6-7 h.  All duplex DNA samples were heated at 
80°C for 10 min, slowly cooled and loaded in 90mM Tris-borate (pH 8.0), 10% 
glycerol, and 50mM magnesium chloride.  DNA samples contained 0.63 mM 
per strand.  Gels were visualized by UV shadowing and then photographed. 
ease composition analysis 
Base composition analysis was performed on 0.5 OD units of oligomer with 
snake venom phosphodiesterase  I  (2  units)  and  alkaline  phosphatase  (10 
units) in 30mL of 50 mM Tris (pH 8.9) containing 10mM magnesium chloride. 
After 8 h at 37°C, digestion mixtures were ultrafiltered (3,000 dalton  cut off) 
and analysed by reverse phase HPLC (isocratic 4% acetonitrile  in 0.1M 
triethylammonium acetate pH 7).  Nucleosides were detected at 260 nm and 
identified by comparison with authentic  samples. 74 
4-Methylcoumarin (3) 
o-Hydroxyacetophenone  (1, 1.203 mL, 10 mmol) was added via syringe to a 
solution  of  carboethoxymethylenetriphenylphosphoranel 0 1  (2, 5 g, 15 
mmol) in toluene (25 mL) .  The resulting solution was heated at reflux for 22 
h.  The reaction was cooled to room temperature and filtered to remove the 
precipitated  triphenylphosphine  oxide.  Solvent  was removed  and  the 
resulting  residue  purified  by  flash  chromatography  (silica,  3:1 
hexane:ethylacetate)  to give 1.46 g (91% yield) of a light yellow solid mp 
(81.5-82°C). 1H NMR (300 MHz, DMSO-d6): 8 7.78 (d, 1H, J=7.6 Hz), 7.63 (t, 1H, 
J=7.7 Hz), 7.38(m, 2H), 6.41 (s, 1H), 2.44 (s, 3H).  IR (KBr):  3064; 2988; 1729; 
1684; 1607 cm-1. EIMS, m/z (rel intensity):  160.1 (M+, 56); 132 (70); 131 (100); 
63 (68).  Anal. Calc'd for C1011802: C, 74.99; H, 5.03. Found: C, 74.97; H, 4.96. 
4- Methyl -6- nitrocoumarin (4) 
4-Methylcoumarin  (3, 2.9  g,  18 mmol) was dissolved  in  12.55 mL conc 
sulfuric  acid.  A 3:1  sulfuric  acid/nitric  acid solution  (v/v, 3.023 mL) was 
added at 0°C and stirred for 2 h.  The reaction mixture was poured onto ice 
and the product collected by filtration and dried.  The crude product was 
treated  with chloroform  to  remove any unreacted  starting  material  which 
could be recovered for later use.  The insoluble materials were removed by 
filtration and recrystallized from glacial  acetic  acid to  give  1.385 g (66% 
yield) as fine yellow needles mp (204-206°C). 1H NMR (300 MHz, DMSO-d6): 8 
8.54 (d, 1H, J=2.6 Hz), 8.43 (dd, 1H, J=9.1, 2.7 Hz), 7.62 (d, 1H, J=9.0 Hz), 6.60 (s, 
1H), 2.53 (s, 3H). IR (KBr):  3114; 3085; 1772; 1733; 1632; 1618 cm-1. EIMS, m/z 75 
(rel. intensity):  205 (M+, 100); 177 (49); 131 (55); 103 (45); 77 (72); 63 (27). 
Anal. Calc'd for CIOH7NO4: C, 58.54; H, 3.44; N, 6.83. Found: C, 58.66; H, 3.37; N, 
6.61. 
3 -Bromo-4-methy1-6-nitrocoumarin (5) 
Bromine (9.1 mL, 180 mmol) was added to 4- methyl -6- nitrocoumarin (4, 1.385 
g, 7 mmol) in a round bottomed flask equipped with a condenser and drying 
tube, and the heterogeneous solution  stirred  at room temperature for 48 h. 
Dichloroethane (50 mL) was added and excess bromine reduced with aqueous 
sodium bisulfite.  The organic layer was dried (Na2SO4) and solvent removed 
to give 1.794 g (94% yield) of a white solid which was recrystallized from 
glacial acetic acid mp (202.5-203°C). 1H NMR (300 MHz, DMSO-d6): 8 8.65 (d, 
1H, J=2.6 Hz), 8.48 (dd, 1H, J=9.1, 2.6 Hz), 7.69 (d, 1H, J=9.1 Hz), 2.70 (s, 3H). IR 
(KBr):  3111; 1732; 1623; 1600 cm-1.  EIMS, m/z (rel. intensity):  285 (93); 284 
(M+, 8); 283 (100); 176 (47); 130 (53); 102 (86); 76 (57); 75 (63); 63 (67).  Anal. 
Calc'd for C1oll6NO4Br: C, 42.28; H, 2.13; N, 4.93; Br, 28.13. Found: C, 42.33; H, 
2.06; N, 4.75; Br, 28.29. 
Methyl  3- methyl -5- nitro- 2- benzofurancarboxylate (6) 
Sodium methoxide in methanol (10.9 mL, 5.26 M) was added to a solution of 3­
bromo-4-methyl -6-nitrocoumarin  (5, 10.9 g, 38.4 mmol) in dry methanol 
(104 mL).  The reaction mixture was heated at reflux for 11 h.  The solution 
was cooled to room temperature, neutralized with 6M HCl and filtered.  The 
collected crystals were washed with water and  air  dried.  Recrystallization 
from EtOH gave 6.93 g (77% yield) mp (142-143°C). 1H NMR (300 MHz, DMSO­76 
d6): 8 8.80 (d, 1H, J=2.1 Hz), 8.39 (dd, 1H, J=2.4, 9.2 Hz), 7.93 (d, 1H, J=9.1 Hz), 3.95 
(s, 3H), 2.64 (s, 3H).  EIMS, m/z (rel. intensity):  235 (M+, 100); 204 (59); 102 
(60); 76 (42); 75 (31); 63 (26).  IR (KBr):  3109; 1732; 1528 cm-1.  Anal. Calc'd 
for C11H9N05: C, 56.18; H, 3.86; N, 5.96. Found: C, 55.93; H, 3.80; N, 5.84. The 
solvent was removed from the  filtrate  and the residue  treated  with ethyl 
acetate.  Insoluble  materials  were  filtered  and  the  resulting  solution 
extracted with 10% NaHCO3 (3X).  The aqueous layers were combined and 
neutralized with 6M HCl to give 1.332 g (16% yield) of the corresponding acid 
(8). 
Methyl  3- bromomethyl -5- nitro -2- benzofurancarboxylate (7) 
Methyl  3- methyl -5- nitro -2- benzofurancarboxylate  (6, 180 mg, 0.8 mmol) 
was heated in an oil bath until  it melted.  N-Bromosuccinamide (204 mg,  1 
mmol) was added in portions, making sure all  dissolved.  This mixture was 
heated at 140°C for 2h.  The reaction was cooled slightly and chloroform (2 
mL) added before the mass solidified.  Carbon tetrachloride (6 mL) was added 
and  the  solution  filtered  to  remove  precipitated  succinamide.  The 
remaining  solution  was washed  with  aqueous  sodium  bisulfite,  aqueous 
sodium bicarbonate, and water, dried (Na2SO4) and solvents removed.  The 
off-white residue was recrystallized from Me0H yielding 164 mg (68% yield) 
mp (127-129°C). 1H NMR (300 MHz, DMSO-d6): 8 8.96 (d, 1H, J=2.3 Hz), 8.45 (dd, 
1H, 1=9.1, 2.4 Hz), 8.03 (d, 1H, J=9.2 Hz), 5.26 (s, 2H), 3.98 (s, 3H).  IR (KBr): 
3102; 1726; 1580; 1529 cm-1.  EIMS, m/z (rel. intensity):  315 (9); 314 (M+, 1); 
313 (7); 234 (100); 188 (16); 75 (15); 63 (8).  Anal. Calc'd for Ci iH8N05Br: C, 
42.06; H, 2.57; N, 4.46. Found: C, 42.36; H, 2.53; N, 4.34. 77 
3- Methyl -5- nitro -2- benzofurancarboxylic  acid (8) 
To  a  solution  of methyl  3- methyl -5- nitro -2- benzofurancarboxylate  (6, 213 
mg, 0.9 mmol) in methanol (2 mL) was added 1M aqueous NaOH (1 mL).  The 
solution was heated at reflux for  1  h.  The solution was neutralized with 6 M 
HC1 after cooling to room temperature and filtered.  The white solid (mp 285 ­
286°C dec.) was washed with water and dried to give 190 mg (95% yield).  1H 
NMR (300 MHz, DMSO-d6): 8 8.77 (d, 1H, J=2.3 Hz); 8.37 (dd, 1H, J=2.3, 9.1 Hz); 
7.91 (d,1H, J=9.1 Hz); 2.63 (s, 3H).  IR (KBr):  3109.3; 1698.5; 1686.3 cm-1. Neg. 
FABMS, m/z (rel. intensity):  220.1 (M-1, 100); 176.0 (38).  HRMS (Neg. FAB): 
Calc'd for Ct 0H7NO 5  221.0324.  Found 220.0246 (M-1).  Anal. Calc'd for 
Cioll7N05: C, 54.29; H, 3.19; N, 6.34. Found: C, 54.31; H, 2.92; N, 6.05. 
Methyl  5- amino -3- methyl -2- benzofurancarboxylate (9) 
Pd/C (5%, 213 mg) was added to  a solution of methyl 3- methyl -5- nitro -2­
benzofurancarboxylate  (6, 213 mg, 0.9 mmol) in benzene (10 mL).  The 
solution was shaken in a Parr apparatus (40 psi H2) for  1  h.  Solvent was 
removed  in vacuo  leaving 184 mg (99 % yield) of a yellow solid mp (158 ­
160°C). 1H NMR (300 MHz, DMSO-d6): 8 7.31 (d,1H, J=8.8 Hz); 6.83 (dd,1H, J=2.4, 
8.8 Hz); 6.76 (d,1H, J=2.2 Hz); 5.05 (s,2H); 3.85 (s,3H); 2.43 (s,3H).  IR (KBr): 
3372.8; 1700.7; 16948.4 cm-1.  Pos. FABMS, m/z (rel. intensity):  205.1 (M +, 
100); 154.1 (17).  HRMS (Neg. FAB):  Calc'd for CIOH9NO3 205.0739.  Found 
205.0738 (M -I-). 
Test dimer (11) 78 
1- Methyl -2- chloropyridinium  iodide  165 mg (1.3  mmol) was added  to  a 
solution  of  3- methyl -5- nitro- 2- benzofurancarboxylic  acid  (8, 95 mg, 0.4 
mmol),  hydroxybenztriazole  monohydrate  (73  mg,  0.4  mmol)  and 
triethylamine  (0.25 mL) in  dry methylene chloride  (2 mL) at  0° C.  The 
solution was stirred  for  lh,  then poured  into  0.05 M HCl diluted  with 
methylene  chloride.  The  solution  was  washed  with  water  and  dried 
(Na2SO4).  Solvent was removed in  vacuo  leaving a dark brown oil which 
was  contaminated  with  triethylamine  and  N- methyl -2- pyridinone.  This 
crude HOBt ester in DMF (1.5 mL) was added to a solution of methyl 5- amino­
3- methyl -2- benzofurancarboxylate  (9, 88 mg 0.4 mmol) in dry DMF (1 mL). 
The solution was stirred  at room temperature for  lh.  After partial removal 
of solvent under high vacuum, 2:1  methanol in water (50 mL) was added. 
The solution was filtered and crystals air dried to give 88 mg of a yellow solid 
(50% yield).  1H NMR (DMSO-d6): 8 10.78 (s, 1H); 8.84 (dd, 1H); 8.43 (dd, 1H); 
8.36 (d, 1H); 7.93 (d, 1H); 7.89 (dd, 1H); 7.72 (d, 1H); 3.93 (s, 3H); 2.71 (s, 3H); 
2.56 (s, 3H). 
1((2-Methoxycarbony1-5-nitro-3-benzofuranynmethyDcytosine (13) 
A solution  of methyl  3-bromomethy1-5-nitrobenzofurancarboxylate  (7,  1.084 
g, 3 mmol) in dry DMSO (6 mL) was added via syringe to a solution of cytosine 
(12, 606 mg, 5 mmol) and potassium t-butoxide (611 mg, 5 mmol) in dry DMSO 
(6 mL).  This solution was stirred under an atmosphere of N2 at room 
temperature  overnight.  The  reaction  was  quenched  with  20%  acetic 
acid/methanol  (6 mL) and the solvents removed under high vacuum.  The 
residue was  stirred  with 50% methanol/chloroform (2X) and  filtered  to 79 
remove the insoluble product.  An additional quantity was obtained by flash 
chromatography  (silica,  15% methanol/chloroform)  to  give a  total  yield of 
906 mg (79% yield) of an off white solid mp (222-225°C dec.).  1H NMR (300 
MHz, DMSO-d6): 6 8.81 (d, 1H, J=2.1 Hz), 8.40 (dd, 1H, J=9.2, 2.0 Hz), 7.99 (d, 1H, 
J=9.2 Hz), 7.78 (d, 1H, J=7.3 Hz), 7.26 (br d, 2H), 5.74 (d, 1H, J=7.3 Hz), 5.38 (s, 
2H), 3.98 (s, 3H).  IR (KBr):  3382.3;  3106.0; 1732.5; 1719.6;  1701.9 cm-1.  Neg. 
FABMS, m/z (rel.  intensity):  343.1  (M-1, 36); 311.1 (80);  283.3 (100);  255.3 
(41); 215.1 (35). HRMS (Neg. FAB):  Calc'd for C15H12N406 344.0758; Found 
343.068 (M-1). 
1- ((2- Methoxycarbonyl -5- nitro- 3- benzofuranyl)methyl)uracil (14) 
Trifluoroacetic acid (0.3 mL) and acetic acid (0.3 mL) were added to  1-((2­
methoxycarbony1-5-nitro-3-benzofuranyl)methyl)cytosine  (13, 45 mg, 0.3 
mmol) at room temperature.  Sodium nitrite (35 mg, 0.51 mmol) was added to 
the homogeneous solution and a solid formed after 10 min.  Additional TFA 
(0.2 mL), HOAc (0.2 mL) and sodium nitrite (35 mg, 0.51 mmol) was added 
after 2 h.  The reaction was quenched by the addition of water after  11  h. 
The resulting white solid (mp 270°C dec.) was collected by filtration, washed 
with water and dried (31 mg, 69% yield)  1H NMR (300 MHz, DMSO-d6): 8 11.45 
(br s, 1H); 8.83 (d, 1H, J=2.3 Hz); 8.42 (dd, 1H, J=2.3, 9.2 Hz); 8.01 (d, 1H, J=9.2 
Hz); 7.79 (d, 1H, J=8.0 Hz); 5.63 (dd, 1H, 1=2.0, 7.9 Hz); 5.39 (s, 2H); 3.98 (s, 3H). 
IR (KBr):  3095.1; 3050.6; 3030.9; 1730.8; 1717.8; 1694.6 cm-1.  Neg. FABMS, m/z 
(rd. intensity):  344.1 (M-1, 38); 266.1 (74); 113.0 (100).  HRMS (Neg. FAB): 
calc'd for Ci5HliN307 345.0579.  Found 344.0519 (M-1). 80 
94(2-Methoxycarbon_y1-5-nitro-3-benzoluranyl)me_thy_l)-6-chlo_ropAirine 
(16) 
A solution  of methyl  3- bromomethyl -5- nitro -2- benzofurancarboxylate  (7, 1 
g, 4 mmol) in dry DMSO (7.5 mL) was added via syringe to a solution of 6­
chloropurine  (15, 853 mg, 6 mmol) and potassium t-butoxide (620 mg, 6 
mmol) in dry DMSO (7.5 mL).  This solution was stirred at room temperature 
under an atmosphere of N2 overnight.  The reaction was quenched with 20% 
acetic  acid  in  methanol  (6.1  mL) and  the  solvents removed under high 
vacuum.  The residue was  stirred  with methanol and  insoluble  materials 
filtered  and washed with  water.  Additional  product  precipitated  out  of 
solution on standing to give a total yield of 855 mg (80% yield) mp (155 ­
157°C, dec.). 1H NMR (300 MHz, DMSO-d6): 8 8.88 (d, 1H, J=2.3 Hz); 8.80 (s, 1H); 
8.78 (s, 1H); 8.39 (dd, 1H, J=2.3, 9.2 Hz); 8.00 (d, 1H, J=9.1 Hz); 6.06 (s, 2H); 3.98 
(s, 3H).  IR (KBr):  3434.1; 3101.3; 1732.9; 1719.2; 1698.5; 1686.5 cm-1.  Neg. 
FABMS m/z, (rel. intensity):  155.1 (56); 232.0 (54); 386.1 (M-1, 100).  HRMS 
(Neg. FAB): Calc'd for Ci6Hi0N505 387.0370, Found 386.029 (M-1). 
94(2-Methoxycarbony1-5-nitro-3-benzofuranyl)methylThypoxanthine (17) 
Tetramethylguanidine (0.15 mL,  1  mmol) was added  to  a  solution  of 2­
pyridinealdoxime  (158  mg,  1  mmol) and  9((2-methoxycarbony1-5-nitro-3­
benzofuranyl)methyl)-6-chloropurine  (16, 50 mg, 0.1 mmol) in dry DMSO (1 
mL).  The reaction  was  stirred  under  an  atmosphere  of N2  at room 
temperature overnight.  The reaction was quenched with 20% acetic acid in 
methanol (until neutral to litmus), water was added and the solution filtered. 
The collected crystals were washed with water and dried  to give 38 mg (79% 81 
yield).  1H NMR (300 MHz, DMSO-d6): 8 12.40 (br  s, 1H); 8.69 (d,1H, J=2.3 Hz); 
8.40 (dd, 1H, J=2.3, 9.1 Hz); 8.22 (s, 1H); 8.12 (d, 1H, J=4.3 Hz); 8.00 (d, 1H, J=9.1 
Hz); 5.95 (s, 2H); 4.03 (s, 3H). 
94(2-Methoxycarbony1-5-nitro-3-benzofuranyl)methyl)-6-chloro-7­
deazapurine (19) 
A solution  of  methyl  3- bromomethyl -5- nitro- 2- benzofurancarboxylate  (7, 
140 mg, 0.44 mmol) in dry DMSO (2 mL) was added to a solution of 6-chloro-7­
deazapurine  (18, 68 mg, 0.44 mmol) and potassium t-butoxide (50 mg, 0.44 
mmol) in dry DMSO (0.5 mL).  This solution was stirred at room temperature 
under an atmosphere of N2 overnight.  The reaction was quenched with 20% 
HOAc in Me0H (1 mL), filtered and the white solid (mp 207-208°C) obtained 
washed with Me0H (90 mg, 52% yield).  1H NMR (300 MHz, DMSO-d6): 8 8.73 (s, 
1H); 8.50 (d, 1H, J=2.2Hz); 8.35 (dd, 1H, J=2.3, 9.2 Hz); 7.98 (d, 1H, J=9.2 Hz); 7.86 
(d, 1H, J=3.6 Hz); 6.73 (d, 1H, J=3.5 Hz); 6.05 (s, 2H); 4.01 (s, 3H).  IR (KBr): 
3094.7; 3054.2; 2957.2; 1713.9; 1623.1; 1604.4 cm-1.  Neg. FABMS, m/z (rel. 
intensity):  386.1 (NI', 100); 327.1 (34); 188.1 (44).  HRMS (Neg. FAB):  calc'd 
for Ci 7111 1 N4 0 5 Cl  386.0419.  Found 386.0419  (Mi.).  Anal Calc'd for 
C27H11N405C1: C, 52.80; H, 2.87; N, 14.49. Found: C, 52.51; H, 3.14; N, 14.84. 
9((2-Methoxycarbony1-5-nitro-3-benzofuranynmethyl)-6-azido-7­
deazapurine 
Sodium azide  (18  mg,  0.3  mmol) was added  to  a  solution  of  9-((2­
methoxycarbony1-5-nitro-3-benzofuranyl)methyl)-6-chloro-7-deazapurine 
(19, 100 mg, 0.3 mmol) in dry DMSO (5 mL).  This solution was heated to 65°C 82 
and stirred under an atmosphere of N2.  An additional 0.5  equivalents of 
sodium azide (9 mg, 0.15 mmol) was added after 6 h and heating continued 
overnight.  This solution was cooled and water added, causing a solid to form. 
This was collected  via  filtration  and air  dried, 92 mg (90% yield) was 
obtained mp (211-212°C, dec.).  11i NMR (300 MHz, DMSO-d6): 8 9.96 (s, 1H); 
8.39 (d, 1H, J=2.2 Hz); 8.34 (dd, 1H, J=2.2, 9.1 Hz); 7.98 (d, 1H, 3=9.0 Hz); 7.90 (d, 
1H, J=3.4 Hz); 7.16 (d, 1H, J=3.4 Hz); 6.17 (s, 2H); 4.02 (s, 3H). IR (KBr):  3112.9; 
3097.5;  3093.7;  3091.5; 3087.7; 1739.3; 1734.6;  1730.7;  1726.3;  1724.0;  1716.8; 
1700.8  cm-1.  Pos. FABMS, m/z (rel. intensity):  394.0  (M+1,  58); 154.1  (100); 
136.0 (74). HRMS (Pos. FAB):  Calc'd for C27H11 N705 393.0823.  Found 394.0900 
(M+1). 
9((2-Methoxycarbony1-5-nitro-3-benzofuranyl)methyl)-6-amino-7­
sieazapurine (20) 
To  50  mg  (0.13  mmol)  9-((2-methoxycarbony1-5-nitro-3­
benzofuranypmethyl)-6-azido-7-deazapurine was added 30% HBr in HOAc 
(0.53 mL), HOAc (0.53 mL), and phenol (23.9 mg, 0.25 mmol).  This solution 
was heated to 60°C for  h, cooled to room temperature and stirred  for an 1 
additional 24 h.  Excess HBr was blown off with N2.  The remaining solution 
was  triturated  with  petroleum  ether  to  remove  residual  HOAc.  The 
remaining orange oil was treated with Na2C0 3  (aq., 1M) which caused a 
yellow solid to form which was collected via filtration (40  mg, 85% yield mp 
(230-232°C, dec.)). 1H NMR (300 MHz, DMSO-d6): 8 8.45 (d, 1H, J=2.2 Hz); 8.33 
(dd, 1H, J=2.3, 9.2 Hz); 8.17 (br s, 1H); 7.96 (d, 1H, J=9.2 Hz); 7.26 (d, 1H, 1=3.5 
Hz); 7.12 (br s, 2H), 6.60 (d, 1H, 3=3.4 Hz); 5.87 (s, 2H); 4.03 (s, 3H).  IR (KBr): 
3405.0; 1733.4; 1651.9 cm-1.  Pos. FABMS, m/z (rel. intensity):  368.1 (M+1, 51); 83 
154.1 (100); 136.0 (74).  HRMS (Pos. FAB):  Calc'd for C27H 13N505 367.0918. 
Found 368.0996 (M+1). 
5-(2.5.8.11-Tetraoxadodecyl)cytosine (22) 
Triethylene  glycol  monomethyl  ether  (0.8  mL) and  triethylene  glycol 
monomethyl  ether/HCI  (180  ta..,  3.4 M) were added  to  5-hydroxymethyl 
cytosine116 (21, 100 mg, 0.7 mmol) and heated to 100°C.  An additional 60 ILL 
of triethylene glycol monomethyl ether/HC1  (3.4 M) was added  after 5  h. 
Heating was continued  for  an  additional  7  h.  The reaction mixture was 
cooled, diluted with diethyl ether (10 mL) and filtered.  The obtained solid 
was  treated  with  10% methanol  in  chloroform  and  filtered  to  remove 
insoluble  material.  This  dissolved  material  was  purified  by  flash 
chromatography (silica, 10% methanol in chloroform) to give 123 mg (61% 
yield) of product as a white solid (mp 117-118°C). 1H NMR (300 MHz, DMSO­
d6): 810.44 (br s, 1H); 7.37 (s, 1H); 7.16 (br s, 1H); 6.46 (br s, 1H); 4.16 (s, 2H); 
3.46 (m, 12 H); 3.32 (s, 3H).  IR (KBr):  3441.1; 3125.6; 2890.1; 2817.3; 2812.8; 
1695.4; 1671.5 cm-1.  Pos. FABMS, m/z (re. intensity):  288.1 (M+1, 100); 124.0 
(43).  HRMS (Pos. Fab):  Calc'd for Ci2H21N305 287.1512.  Found 288.1559 
(M+1).  Anal. Calc'd for C12H21N305: C, 50.16; H, 7.37; N, 14.62.  Found:  C, 
50.35; H, 7.37; N, 14.58. 
4-(N-Benzoy11-5-(2.5.8.11-tetraoxadodecyncytosine (23) 
Dry pyridine (1.4 mL) and benzoyl chloride (104 ttL, 0.9 mmol) were added to 
5-(2,5,8,11-tetraoxadodecyl)cytosine  (22, 170 mg, 0.6 mmol)  .  The reaction 84 
mixture was stirred  at room temperature under an atmosphere of N2 for 6.5 
h.  The solution was cooled  in  an ice bath and the reaction quenched by 
addition of 184 AL water, stirred  for 5 min, and followed by 184 AL of 
ammonium hydroxide.  Solvent was removed and the resulting  oil  treated 
with chloroform and  filtered  to remove insoluble  material.  This  solution 
was  applied  directly  to  a  silica  gel  column  and  purified  by  flash 
chromatography (silica, 2.5% methanol in chloroform) to give 183 mg (79% 
yield) mp (47-49°C). 1H NMR (300 MHz, DMSO-d6): 812.96 (br s, 1H); 11.71 (br 
s, 1H); 8.19 (d, 2H, J=7,8 Hz); 7.71 (s, 1H); 7.57 (t, 1H, J=7.4 Hz); 7.49 (t, 2H, J=7.6 
Hz); 4.40 (s, 2H); 3.48 (m, 12 H); 3.22 (s, 3H).  IR (KBr):  2895.8; 2881.4; 2.876.4; 
1706.6;  1624.9; 1561.0 cm-1.  Pos. FABMS, m/z (rel. intensity):  392.1 (M+1, 
100); 228.1 (51); 105.1 (61). HRMS (Pos. FAB): Calc'd for C19H25N306 391.1780. 
Found 392.18240 (M+1). Anal. Calc'd for C19H25N306: C, 58.30; H, 6.44; N, 
10.74. Found: C, 58.57; H, 6.43; N, 10.46. 
j4(2-Methoxycarbony1-5-nitro-3-benzofuranyllmethyl)-44N-benzoy1)-5­
f 2 .5 .8 .1 1 - te tr ao x ad o d e cy ncytosine (24) 
Methyl  3- bromomethyl -5- nitro -2- benzofurancarboxylate  (7, 207 mg, 0.66 
mmol)  in  dry DMSO (1.5  mL) was  added  to  4-(N-benzoy1)-5-(2,5,8,11­
tetraoxadodecy1)-cytosine  (23, 280 mg, 0.72 mmol) and potassium t-butoxide 
(80 mg, 0.72 mmol) in dry DMSO (1.8 mL).  The resulting solution was stirred 
at room temperature for 18 h.  Reaction was quenched by the addition of 20% 
acetic  acid  in  methanol  (2  mL)  and  solvents  removed.  Flash 
chromatography of the  residue  (silica,  3:1  ethyl  acetate:hexane) gave 358 
mg (87% yield) of product as a white solid mp (99.5-101°C). 1H NMR (300 
MHz, DMSO-d6): 8 13.00 (br s, 1H); 8.92 (d, 1H, J=2.3 Hz); 8.41 (dd, 1H, J=2.3, 9.1 85 
Hz); 8.15 (d, 2H, J=7.2 Hz); 8.09 (s, 1H); 8.01 (d, 1H, J=9.2 Hz); 7.58 (t, 1H, J=7.3 
Hz); 7.50 (t, 2H, J=7.7 Hz); 5.51 (s, 2H); 4.42 (s, 2H); 3.99 (s, 3H); 3.50 (m, 12 H); 
3.19 (s, 3H).  IR (KBr):  2875.2; 2867.5; 1725.0; 1719.4; 1701.8 cm-1.  Pos. FABMS, 
m/z (rel. intensity):  625.2 (M+1, 71); 461.1 (50); 105.1 (100). HRMS (Pos. FAB): 
Calc'd for C301132N4011 624.2113.  Found 625.21450 (M+1).  Anal. Calc'd for 
C301132N4011: C, 57.69; H, 5.16; N, 8.97. Found: C, 57.80; H, 5.13; N, 8.84. 
5-(2.5.8.11-Tetraoxadodecyfluracil (26) 
To 5-hydroxymethyl  uracil  (25,  100 mg, 0.7 mmol) was added triethylene 
glycol  monomethyl  ether  (0.8  mL)  and  triethlene  glycol  monomethyl 
ether/HC1  (2.5 M, 160  ILL).  This solution was heated at 100°C under an 
atmosphere of N2 for 12 h.  The reaction mixture was then cooled, diluted 
with 10% Me0H in CHC13 and purified by flash chromatography (silica, 0-5% 
Me0H in CHC13).  This provided 98 mg (48% yield) of product as a white solid. 
mp (119-121°C). 1H NMR (300 MHz, DMSO-d6): 8 11.09 (br s, 1H); 10.81 (br s, 
1H); 7.40 (s, 1H); 4.09 (s, 2H); 3.44 (m, 12H); 3.23 (s, 3H).  IR (KBr):  3086.6; 
2876.6; 2859.8; 1740.8; 1671.7 cm-1.  Pos. FABMS, m/z (rd. intensity):  289.1 
(M+1, 66); 165.2 (100); 125.0 (44); 59.1 (38).  HRMS (Pos. FAB):  Calc'd for 
C12H20N206 288.1321. Found 289.14000 (M+1). Anal. Calc'd for C12H2ON206: 
C, 49.99; H, 6.99; N, 9.72. Found: C, 50.38; H, 6.80; N, 9.56. 
14(2-Methoxycarbony1-5-nitro-3-benzofuranyl)methyl)-5-(2.5.8.11­
tetraoxadodecynuracil (27) 
A solution  of  methyl  3- bromomethyl -5- nitro -2- benzofurancarboxylate  (7, 
328 mg, 1.04 mmol) in dry DMSO (2 mL) was slowly added via syringe to  a 86 
solution  of  5-(2,5,8,11-tetraoxadodecyl)uracil  (25, 601 mg, 2.08 mmol) and 
potassium t-butoxide (234 mg, 2.08 mmol) in dry DMSO (6 mL).  This reaction 
mixture was stirred  at room temperature under an atmosphere of N2 for 12 
h.  The reaction was then quenched with 20% HOAc in Me0H (1 mL) and 
solvent removed.  The resulting residue was taken up in CHC13, filtered to 
remove insoluble  materials  and  purified  by  flash  chromatography  (silica, 
CHC13) providing 275 mg (50% yield) product as a white solid mp (145-146°C). 
1H NMR (300 MHz, DMSO-d6): 8 11.51 (br s, 1H); 8.85 (d, 1H, J=2.4 Hz); 8.41 (dd, 
1H, 1=2.4, 9.2 Hz); 8.00 (d, 1H, J=9.2 Hz); 7.81 (s, 1H); 5.40 (s, 2H); 4.12 (s, 2H); 
3.98 (s, 3H); 3.40 (m, 15H).  IR (KBr):  3151.0; 3148.9; 3101.2; 2956.5; 2944.5; 
2923.2; 2822.9; 1737.7; 1692.8 cm-1.  Pos. FABMS, m/z (rel. intensity):  522.3 
(M +1, 36); 358.1 (71); 307.1 (28); 234.1 (33); 154.1 (100); 136.0 (66). HRMS (Pos. 
FAB):  Calc'd for C23H27N3011 521.1684, Found 522.17230 (M+1).  Anal Calc'd 
for C23H27N3011: C, 52.97; H, 5.22; N, 8.06. Found: C, 53.03; H, 5.07; N, 7.91. 
14(5-Amino-2-methoxycarbony1-3-benzofuranyhmethyl)-4-(N-benzoy1)-5­
12.5.8.11-tetraoxadodecyllcytosine (29) 
Pd/C  (10%,  275  mg)  was  added  to  1((2-methoxycarbony1-5-nitro-3­
benzofuranly)methyl)-4-(N-benzoy1)-5-(2,5,8,11-tetraoxadodecyl)cytosine 
(24, 275 mg, 0.44 mmol) in benzene (4 mL).  The reaction was shaken in a 
Parr apparatus under 40 psi H2 for 40 min.  Solution was filtered through 
celite and solvent removed.  Flash chromatography of the residue (silica, 1% 
methanol in  chloroform) gave 197 mg (75%) of a yellow solid mp (128­
130°C). 1H NMR (300 MHz, DMSO-d6): 513.12 (br s, 1H); 8.18 (d, 2H, J=6.8 Hz); 
7.92 (t, 1H, 1=5.7 Hz); 7.59 (t, 1H, 1=5.7 Hz); 7.49 (t, 2H, J=7.9 Hz); 7.39 (d, 1H, J=8.9 
Hz); 6.84 (dd, 1H, J=2.2, 8.9 Hz); 6.72 (d, 1H, 1=1.9 Hz); 5.41 (s, 2H); 5.15 (s, 2H); 87 
4.40 (s, 2H); 3.92 (s, 3H); 3.61 (m, 12 H); 3.19 (s, 3H).  IR (KBr):  3398.3; 2876.8; 
2867.8; 2861.4;  1733.5;  1717.5; 1707.7;  1700.6;  1698.4 cm-1.  Pos. FABMS, m/z 
(rel. intensity):  595.2  (M+1, 93); 204.1  (100);  105.0 (96).  HRMS (Pos. FAB): 
Calc'd for C30H34N409 594.2375. Found 595.24070 (M+1). 
14(5-BOC-amino-2-methoxycarbonyl-3-benzofuranyllmethyl)-4-(N­
benzoy1)-5-(2.5.8.11-tetraoxadodecyl)cytosine (30) 
Di-tert-butyl dicarbonate (28.7 AL, 0.125 mmol) was added to  14(5-amino-2­
methoxycarbony1-3-benzofuranyl)methyl)-4-(N-benzoy1)-5-(2,5,8,11­
tetraoxadodecyl)cytosine  (29, 67 mg, 0.11 mmol) in methylene chloride (4.3 
mL) and ethanol (0.8 mL).  The reaction was stirred at room temperature for 
6 days.  Solvents were removed and the resulting residue purified by flash 
chromatography (silica, 2.5% methanol in chloroform)  to give 76 mg (97% 
yield) of product as an off-white solid mp (119-121 °C).  1H NMR (300 MHz, 
DMSO-d6): 513.23 (br s, 1H); 9.47 (s, 1H); 8.19 (d, 2H, J=7.1 Hz); 8.07 (s, 1H); 7.91 
(d, 1H, J=2.2 Hz); 7.50 (m, 5H); 5.49 (s. 2H); 4.47 (s, 2H); 3.94 (s, 3H); 3.46 (m, 
12H); 3.20 (s, 3H); 1.37 (s, 9H).  Eft (KBr):  2923.3; 1704.2; 1694.7; 1684.4 cm-1. 
Pos. FABMS, m/z (rel. intensity):  695.0 (M+1, 93); 474.9 (51); 247.9 (100); 204.0 
(66).  HRMS (Pos. FAB) calc'd for C35H42N4011 694.2852.  Found 695.2928 
(M+1). Anal calc'd for C35H42N4011: C, 60.51; H, 6.09; N, 8.06. Found: C, 60.17; 
H, 6.09; N, 8.19. 
J-((5-B0C-amino-2-carboxy-3-benzofuranynmethyl)-4-(N-benzoy1)-5­
(2.5.8.11-tetraoxadodecyl)cytosine (31) 88 
To  a  solution  of  1-((5-B0C-amino-2-methoxycarbony1-3­
benzofuranypmethyl)-4-(N-benzoy1)-5-(2,5,8,11-tetraoxadodecyl)cytosine 
(30, 153 mg, 0.22 mmol) in dry pyridine (1.5 mL) was added lithium iodide 
(111 mg, 0.83 mmol).  The reaction mixture was heated to reflux for 2 h.  The 
solution was allowed to cool to room temperature  and solvent removed under 
high vacuum.  Water (1.5 mL) was added and this suspension acidified with 
6N HC1 with cooling  in an ice  bath.  This solution was quickly  filtered 
yielding  151 mg of a yellow solid.  Purification by flash chromatography 
(silica,  10% methanol in chloroform) gave 77 mg (51% yield) of a yellow 
solid mp(147-148 °C). 1H NMR (300 MHz, DMSO-d6): 8 13.24 (br s, 1H); 9.44 (s, 
1H); 8.19 (d, 2H, J=6.8 Hz); 8.09 (s, 1H); 7.86 (s, 1H); 7.49 (m, 5H); 5.49 (s, 2H); 
4.46 (s, 2H); 3.39 (m, 15 H); 1.37 (s, 9H). IR (KBr):  3034.3; 3004.3; 1728.1; 1696.3 
cm-1.  Neg. FABMS, m/z (rel. intensity):  679.3 (M-1, 4); 153.1 (100).  HRMS 
(Neg. FAB) calc'd for C34H40N4011 680.2695.  Found 679.2612 (M-1). 
.14(5-Amino-2-methoxycarbony1-3-benzofuranly) nethyl)-542.5.8.11­
tetraoxadodecynuracil (33) 
HC1 (84 jiL)  was added  to  a  solution  of  1-((2-methoxycarbony1-5-nitro-3­
benzofuranly)methyl)-5-(2,5,8,11-tetraoxadodecyl)uracil  (27, 184 mg, 0.35 
mmol) and SnC12.2H20 (289 mg, 1.28 mmol) in dry DMF (5.85 mL) and dry 
Me0H (2.0 mL).  This reaction mixture was stirred at room temperature for 48 
h.  Solvents were partially removed under reduced pressure, water (10 mL) 
was added and the pH adjusted to  8 with NaOH (aq.,  1  M).  Solvent was 
removed from  the  resulting  suspension  and  the  resulting  residue  treated 
with DMF and filtered.  DMF was removed and the residue purified by flash 
chromatography  (silica, 5% Me0H in CHC13), yielding 107 mg (62% yield) 89 
product as a yellow solid mp (149-151°C) 1H NMR (300 MHz, DMSO-d6): 8 
11.44 (br s, 1H); 7.64 (s, 1H); 7.38 (d, 1H, J=8.8 Hz); 6.84 (dd, 1H, J=2.2, 8.9 Hz); 
6.69 (d, 1H, J=2.1 Hz); 5.28 (s, 2H); 5.13 (s, 2H); 4.10 (s, 2H); 3.91 (s, 3H); 3.42 (m, 
10H); 3.32 (s, 2H); 3.22 (s, 3H).  IR (KBr):  3373.0; 2902.1; 2879.1; 1716.3; 1694.6; 
1677.4 cm-1.  Pos. FABMS, m/z (rel. intensity):  492.2 (M+1, 23); 328.1 (45); 
204.1 (100).  HRMS (Pos. FAB):  Calc'd for C23H29N3 09 491.1945.  Found 
492.19820 (M+1). 
.14(5-B0C-amino-2-methozycarbony1-1-benzofuranyl)methyl)-5-(2.5.8.1 1­
tetraoxadodecyfluracil (34) 
Di-tert-butyl  dicarbonate (44 gL, 0.192 mmol) was added to  14(5-amino-2­
methoxycarbony1-3-benzofuranyl)methyl)-5-(2,5,8,1 1­
tetraoxadodecypuracil  (33, 84 mg, 0.17 mmol) in methylene chloride (1 mL) 
and ethanol (0.2 mL).  Reaction was stirred  at room temperature for 3 days. 
Solvents  were  removed  and  the  resulting  residue  purified  by  flash 
chromatography (silica, 2.5% methanol in chloroform)  to give 99 mg (98% 
yield) of product as an off-white solid mp (134-136°C). 1H NMR (300 MHz, 
DMSO-d6): 8 11.40 (br s, 1H); 9.48 (s, 1H); 7.92 (s, 1H); 7.77 (s, IH); 7.60 (d, 1H, 
J=9.0 Hz); 7.45 (dd, 1H, J=2.3, 8.9 Hz); 5.34 (s, 2H); 4.14 (s, 2H); 3.93 (s, 3H); 3.40 
(m, 15 H); 1.48 (s, 9H).  IR (KBr):  3326.8; 2891.7; 2875.4; 1713.3; 1694.8; 1692.7; 
1684.8;  1678.1  cm-1.  Pos. FABMS, m/z (rel.  intensity):  592.1(M+1,  12); 
428.1(12); 372.0 (72); 248.0 (100); 154.1(37); 136.0(37). HRMS (Pos. FAB) calc'd 
for C2 8H 3 7N 3 0 1 1:  591.2429.  Found 592.2504 (M+1).  Anal. calc'd  for 
C281437N3011: C, 56.83; H, 6.31; N, 7.10. Found: C, 57.01; H, 6.15; N, 6.99. 90 
1((5 -B0C-amino-2-carboky-3-benzofuranyl)methyD-5-(2.5.8.11­
ietraoxadodecyfluracil (35) 
14(5-B0C-amino-2-methoxycarbony1-3-benzofuranyl)methyl)-5-(2,5,8,11­
tetraoxadodecyl)uracil  (34, 25 mg, 0.042 mmol) in aqueous NaOH (1 mL) was 
heated to reflux for  1  h.  The reaction mixture was allowed to cool to room 
temperature then cooled in an ice bath prior to acidification with 6M HC1.  A 
solid formed (mp 161-162°C) which was collected via filtration, washed with 
H2O and air dried (15 mg, 62% yield).  1H NMR (300 MHz, DMSO-d6): 8 11.39 
(br s, 1H); 9.41 (s, 1H); 7.86 (s, 1H); 7.84 (s, 1H); 7.54 (d, 1H, J=8.9 Hz); 7.39 (dd, 
1H, J=1.8, 8.9 Hz); 5.36 (s, 2H); 4.12 (s, 2H); 3.36 (in, 15 H); 1.47 (s, 9H).  IR 
(KBr):  3035.9; 3008.4; 2929.4; 2910.1; 1733.1; 1698.4 cm-1.  Pos. FABMS, m/z 
(rel. intensity):  600.1 (M+Na+, 65); 358.0(46); 234.0(100).  HRMS (Pos. FAB) 
calc'd for C27H35N3011 577.2273.  Found 600.2168 (M+Na+).  Anal. Calc'd for 
C27H35N3011: C, 56.13; H, 6.11; N, 7.28. Found: C, 56.41; H, 6.09; N, 7.03. 
C-C dimer (36) 
Dicyclohexylcarbodiimide (9.1 mg, 0.04 mmol) was added to a solution of 1­
((5-B0C-amino-2-carboxy-3-benzofuranly)methyl)-4-(N-benzoy1)-5­
(2,5,8,1 1-tetraoxadodecyl)cytosine  (31,  15  mg,  0.02  mmol)  and 
hydroxybenztriazole (3.4 mg, 0.02 mmol) in  dry CH2C12 (0.22 mL).  This 
solution was stirred  at room temperature under an atmosphere of N2 for 1 h. 
A  solution  of  14(5-amino-2-methoxycarbony1-3-benzofuranyl)methyl)-4­
(N-benzoy1)-5-(2,5,8,11-tetraoxadodecyl)cytosine  (29, 6.6 mg, 0.01 mmol) and 91 
ethyldiisopropylamine  (3.8  gL, 0.04 mmol) in dry CH2C12 (0.11 mL) and dry 
DMF (0.11 mL) was added via syringe.  The resulting solution was stirred at 
room temperature  for  an  additional  3  h.  Solvents were removed under 
reduced pressure and  the remaining residue  treated  with  acetonitrile  and 
filtered  to removed dicyclohexylurea.  The acetonitrile was removed and the 
residue  purified  by  flash  chromatography  (silica,  2.5%  methanol  in 
chloroform) yielding 7 mg (50% yield based on the amine) of a yellow solid. 
1H NMR (300 MHz, DMSO-d6): 8 13.45 (br s, 1H); 12.98 (br s, 1H); 10.84 (br s, 
1H); 9.44 (br s, 1H); 8.44 (s, 1H); 8.16 (m, 4H); 7.80 (m, 5H); 7.49 (m, 8H); 5.57 (s, 
2H); 5.44 (s, 2H); 4.52 (s, 2H); 4.37 (s, 2H); 3.97 (s, 3H); 3.40 (m, 24 H); 3.17 (s, 
3H); 3.16 (s,  3H); 1.38  (s,  9H).  Pos. FABMS, m/z (rel.  intensity):  1279.4 
(M+Na+, 49); 1257.5 (M+1, 100); 1093.4 (20); 375.1 (25).  HRMS (Pos. FAB): 
Calc'd for C64H72N8010 1256.4917. Found 1257.5065 (M+1). 92 
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APPENDIX I
 
Parameters Added to AMBER
 
BOND  Kr  req 
KT-KT  520.  1.450 
KT-N2  481.  1.340 
KT-HC  340.  1.100 
KT-SD  440.  1.704 
KT-C  410.  1.480 
N-KT  410.  1.360 
CT-KT  317.  1.495 
KP-KP  520.  1.370 
KP-ND  440.  1.370 
KP-KA  410.  1.443 
KA-C  410.  1.474 
N-KP  410.  1.420 
ND-C3  337.  1.480 
ND-CT  337.  1.480 
KP-KB  410.  1.443 
KB-C  410.  1.474 
KB-KB  550.  1.320 
KB-HC  340.  1.080 
KP-HC  340.  1.080 
KP-KO  520.  1.370 
ND-KO  440.  1.370 
KP-C  410.  1.460 
KP-CT  317.  1.495 
KA -KA  550.  1.337 
N-CA  481.  1.340 
CW-C  469.  1.460 
ND-H  434.  1.010 
KP-OD  440.  1.370 
OD-CN  440.  1.404 99 
OD-CW  440.  1.404
 
CT-N2  337.  1.463
 
CN-SD  440.  1.700
 
SD-CW  440.  1.700
 
ANGLE  Ki9  iieq
 
KT-KT-KT  70.  112.7
 
KT-KT-HC  35.  126.0
 
KT-KT-SD  70.  107.9
 
KT-SD-KT  70.  97.6
 
KT-KT-C  70.  126.0
 
KT-C-0  80.  122.0
 
KT-KT-CT  70.  123.0
 
N*-CT-KT  80.  112.5
 
KT-C-N  70.  115.0
 
SD-KT-C  70.  126.0
 
SD-KT-HC  35.  126.0
 
KT-KT-N2  70.  126.0
 
SD-KT-N2  70.  126.0
 
N-KT-SD  70.  126.0
 
KT-N2-H2  35.  120.0
 
N-KT-KT  70.  126.0
 
C-N-KT  50.  120.0
 
CT-N-KT  70.  120.0
 
KP-KP-KP  70.  108.0
 
KP-ND-KP  70.  108.0
 
KP-KP-ND  70.  107.5
 
KP-ND-C3  70.  130.5
 
KP-ND-CT  70.  130.5
 
ND-CT-HC  35.  109.5
 
KP-KP-KB  70.  132.2
 
ND-KP-KB  70.  119.9
 
ND-KP-C  70.  119.9
 
KP-KB-KB  70.  125.5
 100 
KB-KB-C  70.  121.4 
N-KP-KP  70.  125.0 
KP-KP-CT  70.  125.0 
KP-CT-N*  80.  112.5 
HC-CT-KP  35.  109.7 
N2-CT-KP  80.  112.5 
C2-N-KP  70.  116.6 
KP-KP-HC  35.  126.4 
ND-KP-HC  35.  126.4 
KB-KB-HC  35.  120.0 
KP-KB-HC  35.  120.0 
KP-KO-KP  70.  108.0 
KO-KP-ND  70.  107.5 
KO-ND-C3  70.  121.2 
KO-KP-KA  70.  132.2 
ND-KP-KA  70.  119.9 
KP-KP-KA  70.  131.0 
KP-KA-KA  70.  126.0 
KA-KA-C  70.  120.0 
N-KP-KO  70.  125.0 
KA -C -N  70.  116.6 
KB-C-N  70.  115.5 
KP-KO-ND  70.  107.5 
KO-KP-KO  70.  108.0 
KP-ND-H  35.  126.0 
KP-1CP-C  70.  132.2 
KP -C-O  80.  122.0 
KP -C -N  70.  115.0 
KP-N-CT  70.  120.0 
N-CT-N*  50.  112.5 
H2-N2-CT  35.  112.0 
H-N-KP  35.  120.0 
HC-KB-C  35.  120.0 
KB-C-0  80.  112.0 
ICA-C-0  80.  120.4 
KP-OD-KP  70.  106.3 101 
OD-KP-HC  35.  112.2 
OD-KP-KP  70.  109.5 
OD-KP-C  70.  117.6 
CW-OD-CN  70.  104.1 
CA-CN-OD  70.  124.3 
C*-CW-OD  70.  112.3 
OD-CW-C  70.  124.3 
CB-CN-OD  70.  112.3 
C*-CB-CT  70.  128.6 
N-CA-CA  70.  120.0 
H-N-CA  35.  120.0 
C-N-CA  50.  120.0 
C*-CW-C  85.  120.0 
NA-CW-C  70.  120.0 
CW-C-N  70.  115.0 
CW -C -O  80.  122.0 
N*-CT-C*  50.  112.5 
CW-CT-N*  50.  112.5 
TORSION  Vn/2  7  n 
X-KT-KT-X  14.3  180.  2 
X-KT-SD-X  6.0  180.  2 
X-KT-N-X  1.0  180.  2 
X-KT-C-X  5.3  180.  2 
X-KP-KP-X  14.3  180.  2 
X-KP-KB-X  1.0  180.  2 
X-KB-KB-X  30.0  180.  2 
X-KB-C-X  1.0  180.  2 
X-KP-ND-X  6.0  180.  2 
X-ND-CT-X  1.4  180.  2 
X-KP-C-X  5.3  180.  2 
X-KP-N-X  1.0  180.  2 
X-KP-KO-X  14.3  180.  2 102 
X-KO-ND-X  6.0  180.  2 
X-KP-KA-X  1.0  180.  2 
X-KP-CT-X  1.0  0.  2 
X-KA-KA-X  30.0  180.  2 
X-CT-C2-X  1.4  180.  2 
X-KA-C-X  1.0  180.  2 
X-KP-OD-X  6.0  180.  2 
X-CN-OD-X  6.0  180.  2 
X-CW-OD-X  6.0  180.  2 
X-CW-C-X  5.3  180.  2 
X-CA-N-X  10.0  180.  2 
KP  KO /-=-/­
SD  I MI)
H 
KA/KB 103 
7 
APPENDIX II 
Chemical Abstracts Names for Key Compounds 
2-Benzofurancarboxylic acid, 3- bromomethyl -5- nitro-, methyl ester 
13 2-Benzofurancarboxylic acid, 2-[[4-amino-2-oxo-1(2H)­
pyrimidinyl]methy1]-5-nitro-, methyl ester 
14 2-Benzofurancarboxylic acid, 2- [[2,4- dioxo-1 -(2H, 4H)­
pyrimidinyl]methy1]-5-nitro-, methyl ester 
17 2-Benzofurancarboxylic acid, 2[[6-oxo-9(6H)-purinyl]methy11-5-nitro-, 
methyl ester 
20 2-Benzofurancarboxylic acid, 24[6-amino-9-pyrrolo[2,3­
d]pyrimidinyl]methy1]-5-nitro-, methyl ester 
22 2(1H)-Pyrimidinone, 4-amino-5-(2,5,8,11-tetraoxadodecy1)­
24 2-Benzofurancarboxylic acid, 5-nitro-3-[[5-(2,5,8,11-tetraoxadodecy1)-4­
amino-2-oxo-1(2H)-pyrimidinylimethyl], methyl ester 
26 2,4(1H, 3H)-Pyrimidinedione, 5-(2,5,8,11-tetraoxadodecy1)­
27 2-Benzofurancarboxylic acid, 5-nitro-34[5-(2,5,8,11-tetraoxadodecy1)-2,4­
dioxo-1(2H, 4H)-pyrimidinyl]methyl], methyl ester 
31 2-Benzofurancarboxylic acid, 5-[[(1,1-dimethylethoxy)carbonyl)]aminoF 
3-[[5-(2,5,8,11-tetraoxadodecy1)-4-[[benzoyliamino]-2-oxo-1(2H)­
pyrimidinyl]methylF 
35 2-Benzofurancarboxylic acid, 5-[[(1,1-dimethylethoxy)carbonylflamino]­
34[5-(2,5,8,11-tetraoxadodecy1)-2,4-dioxo-1(2H,4H)­
pyrimidinyl]methylF 